Latest / CME Outfitters Medical Education / A CaseWise™ Initiative – Mission Possible: Matching Treatment Goals of Patients and Providers in IBD in Clinical Practice
Transcript
- 0:01SPEAKER_04: Well, welcome everybody.
- 0:02SPEAKER_04: It's wonderful to see so many people here today.
- 0:05SPEAKER_04: I'm Miguel Reguero.
- 0:07SPEAKER_04: The activity may include discussions of products and devices that are not currently labeled by the FDA.
- 0:13SPEAKER_04: We will try to avoid that as much as possible.
- 0:16SPEAKER_04: And if we do deviate from that, we will also disclose that as well.
- 0:20SPEAKER_04: I'm Miguel Reguero.
- 0:21SPEAKER_04: I'm the chief of the Digestive Disease Institute at Cleveland Clinic.
- 0:25SPEAKER_04: And I'm going to go down the line and let my panelists introduce themselves.
- 0:29SPEAKER_04: Anita, starting with you.
- 0:31SPEAKER_08: Absolutely.
- 0:31SPEAKER_08: Well, welcome and thank you.
- 0:32SPEAKER_08: Good afternoon.
- 0:33SPEAKER_08: Pleasure being here with my colleagues.
- 0:35SPEAKER_08: I'm Anita Vzali.
- 0:37SPEAKER_08: I'm a professor of medicine at the University of Cincinnati and currently serving as the interim chair of the Department of Medicine.
- 0:44SPEAKER_08: Dr.
- 0:44SPEAKER_08: Barnes?
- 0:46SPEAKER_01: Yes.
- 0:46SPEAKER_01: Hi.
- 0:46SPEAKER_01: Thanks, Anita.
- 0:47SPEAKER_01: I am Ed Barnes.
- 0:48SPEAKER_01: I'm at the University of North Carolina at Chapel Hill.
- 0:52SPEAKER_01: I'm an associate professor of medicine and I'm the co-director of the IBD Center as well.
- 0:56SPEAKER_01: So now I'll pass it over to Angelina to introduce herself.
- 0:59SPEAKER_09: Hi, I'm Angelina Collins.
- 1:01SPEAKER_09: I'm a nurse practitioner at the Inflammatory Bowel Disease Center at University of California, San Diego.
- 1:06SPEAKER_04: And also part of the program, not in the room.
- 1:10SPEAKER_04: Some of these folks are actually at this conference, but they're not actually in the room.
- 1:14SPEAKER_04: This will be a unique program, and I'll come back to this in a minute.
- 1:18SPEAKER_04: But Jessica Allegretti will be highlighted, Ed Loftus will be highlighted, as well as Millie Long.
- 1:25SPEAKER_04: And I think more and more in the world of inflammatory bowel disease, we're trying to include patients and patient voices and stakeholders.
- 1:34SPEAKER_04: So you'll hear from a couple of our patients.
- 1:37SPEAKER_04: They've been active in many of the programs like this at the Congress and others.
- 1:41SPEAKER_04: And it's really a treat to have both Natalie and Kayla today as well.
- 1:47SPEAKER_04: These are our faculty disclosures.
- 1:49SPEAKER_04: They'll also be in your program.
- 1:51SPEAKER_04: Each of us have listed our potential conflicts of interest and our disclosures here, including Jessica, Ed, Milley, Natalie, and Kayla as well.
- 2:03SPEAKER_04: This is also a peered review program, and this goes through the traditional CME vetting.
- 2:09SPEAKER_04: So the learning objectives will be to integrate the latest data and recommendations on IL 23s into your clinical practice and to come up with treatment plans and a shared decision approach with patients.
- 2:24SPEAKER_04: And as a minute I'll get to this, but this is a very case-based presentation.
- 2:29SPEAKER_04: We'll also look at the latest clinical trial efficacy and safety data and utilize the latest and clinical evidence.
- 2:37SPEAKER_04: So this program, just to break it into how this will look, the first part will be a very brief didactic program.
- 2:45SPEAKER_04: I'll go through the efficacy and safety data with the IELTI class.
- 2:50SPEAKER_04: I'll engage my panelists after both the ulcerative colitis and Crohn's portion.
- 2:56SPEAKER_04: But then really the meat of this, which I think is unique, and we'd love your feedback at the end, is we have three wonderful cases that are very real-world.
- 3:06SPEAKER_04: We show the couple of the patients who are involved in this.
- 3:09SPEAKER_04: Now we have adjusted at their permission some of the case to also stimulate some of the discussion.
- 3:16SPEAKER_04: For me, these are cases that I would see in my own practice in Cleveland.
- 3:20SPEAKER_04: I imagine for all of you you would see them.
- 3:22SPEAKER_04: I know our panelists have vetted these as well.
- 3:24SPEAKER_04: And this will stimulate a conversation on the cases that I think will be informational as well.
- 3:31SPEAKER_04: So I'll go through some of the didactics here.
- 3:35SPEAKER_04: The treat-to-target precision care, you know, we've really evolved in the way we've looked at treating both on the left-hand side ulcerative colitis and Crohn's disease on the right-hand side.
- 3:45SPEAKER_04: A theme that I'll mention up front is the early treatment with advanced therapy for both ulcerative colitis and Crohn's disease.
- 3:55SPEAKER_04: This will be a concept you'll hear repeatedly.
- 3:57SPEAKER_04: I know you've heard this in the last few years.
- 3:59SPEAKER_04: You're hearing at the Congress there.
- 4:01SPEAKER_04: But your first therapy early, it's probably the early use is going to be most important.
- 4:07SPEAKER_04: But we'll go through some of the patient characteristics.
- 4:10SPEAKER_04: Access is obviously something that we all live with, and especially the United States, in terms of if we can't access something, that's a barrier.
- 4:18SPEAKER_04: So that's something that we recognize.
- 4:20SPEAKER_04: And then obviously efficacy and safety.
- 4:23SPEAKER_04: Why is the interleukin-23 class important?
- 4:26SPEAKER_04: I remember some of the early GWAS genetic studies where we identified IL-23 as a putative factor in inflammatory bowel disease.
- 4:35SPEAKER_04: It leads to a pathogenic TH17 response, it promotes inflammation.
- 4:40SPEAKER_04: Interestingly, increased IL-23 also may predict resistance to TNF inhibitors.
- 4:47SPEAKER_04: This needs to be borne out in clinical studies, but that may be why some of our patients don't respond to a TNF inhibitor, but do respond to an IL-23 inhibitor.
- 4:58SPEAKER_04: We'll get into the selective IL-23P19 class and go through some of the efficacy and safety.
- 5:05SPEAKER_04: I like this slide because this puts all of the pivotal trials that have been done in interleukin-23s on one slide.
- 5:13SPEAKER_04: In the blue lettering are the ulcerative colitis pivotal trials, and these are the regulatory trials that led to approval of the IL-23s in ulcerative colitis, and kind of in the dark black is the Crohn's disease.
- 5:28SPEAKER_04: And you can see we'll discuss Risen Kissimab, Gasalchiumab, Mericissimab.
- 5:33SPEAKER_04: We'll show the data.
- 5:34SPEAKER_04: And I think one of the nice things, and we'll get to this in a minute, you can take this information with you afterwards.
- 5:40SPEAKER_04: So as mentioned before, there's a lot of data in the first set, but this is something that we really want for you as well.
- 5:48SPEAKER_04: These are busy slides.
- 5:58SPEAKER_04: On this slide, you can see the FDA indications are for all of them ulcerative colitis and Crohn's.
- 6:05SPEAKER_04: But you can see the route of administration, and we'll get into some of the differences of that when we have our panel discussion here in a minute.
- 6:14SPEAKER_04: And then also the efficacy.
- 6:16SPEAKER_04: On the right-hand side, you can see the different efficacy.
- 6:20SPEAKER_04: Again, it's not meant to compare across each of them, but to give you a sense of efficacy.
- 6:26SPEAKER_04: And I'll say up front that the efficacy of these looks similar, but we can't say that in a comparative effective approach.
- 6:33SPEAKER_04: This is risen kissimab, eustacinumab.
- 6:36SPEAKER_04: We'll focus primarily on gaselkimab, maricismab, and risen kissimab.
- 6:42SPEAKER_04: We'll talk about eustacinumab and some of the pivotal head-to-head comparisons, but we're not going to focus on eustacinumab.
- 6:49SPEAKER_04: But if you have questions about eustacinumab, we can certainly do that.
- 6:54SPEAKER_04: Safety, I think you've realized this, and many of you have prescribed these medicines already.
- 7:00SPEAKER_04: To realize the safety with the IL-23 class has been quite good.
- 7:05SPEAKER_04: But you can look at the serious infection rates are quite low, similar to placebo.
- 7:10SPEAKER_04: The most common adverse events are listed, monitoring, which usually TB screening, and we do baseline testing for LFTs, then after induction.
- 7:20SPEAKER_04: That's very similar really for all of them.
- 7:24SPEAKER_04: And then finally for Crohn's disease, again, same thing.
- 7:27SPEAKER_04: Looking at Gasalchimab, Mirinchizimab, Rizinchimab, far right Eustachiniumab.
- 7:33SPEAKER_04: Also safety in Crohn's disease looks quite good.
- 7:37SPEAKER_04: And there's nothing new today in terms of safety we're going to present to you that you have not already seen in the publications and in some of the pivotal presentations.
- 7:47SPEAKER_04: Let me briefly go through some of the ulcerative colitis data, and then you know I'll go through, I'll ask all of you in terms of what your thoughts are at a high level.
- 7:57SPEAKER_04: So we'll go through each of the IL-23s, we'll present the data, and as I mentioned, we'll do ulcerative colitis first, then we'll do Crohn's disease, and then we'll get to the cases.
- 8:08SPEAKER_04: So let's look at clinical remission and endoscopic improvement.
- 8:12SPEAKER_04: So this was the quasar study, and this is the Gaselcumab induction for ulcerative colitis study.
- 8:18SPEAKER_04: You can see in red here is gaselcumab, the 200 milligram IV dose at 0, 4, and 8 weeks, then looking at the 12-week endpoint from left to right, clinical remission, symptomatic remission, response, endoscopic improvement, and HEMI, histologic endoscopic, mucosal improvement.
- 8:39SPEAKER_04: And you can see for each of the endpoints, statistically higher efficacy of gaselcumab compared to placebo in that induction course.
- 8:48SPEAKER_04: And then we look at the maintenance, the week 44 endpoints, and the reason there are two red-shaded is that's gacelculumab sub-Q every four weeks, which is one of the FDA-labeled maintenance doses, or the lighter red, the 100 milligrams every eight weeks subcutaneous.
- 9:08SPEAKER_04: And then again you can see placebo.
- 9:11SPEAKER_04: And you can see the primary and secondary, major secondary endpoints were all met.
- 9:17SPEAKER_04: I'm not going to read through all of them on the bottom, but you can see these were all met for ulcerative colitis.
- 9:23SPEAKER_04: One thing that comes up, and I'm sure it comes up in your own practice, is what if a patient's naive to therapy, or what if a patient's who have already been on an advanced therapy, how do these medicines perform?
- 9:35SPEAKER_04: So this is the gaselcumab study for previously treated patients with ulcerative colitis.
- 9:40SPEAKER_04: On the left-hand side is naive.
- 9:42SPEAKER_04: So that's a patient where gaselcumab in the quasar study was the first therapy the patient received in advanced therapy.
- 9:50SPEAKER_04: And as we've seen with our other studies, you can see a nice delta between the red bar gasalchiumab and the darker bar placebo.
- 10:00SPEAKER_04: And then what about patients who've been on maybe a JAC inhibitor or another biologic, still statistically significant, although barely met with one and a lower response, but still we see a difference between gacelculumab and placebo.
- 10:17SPEAKER_04: I think one area of gaselumab that you've probably all realized now is that there is a subcutaneous induction.
- 10:23SPEAKER_04: So use subcutaneous induction followed by subcutaneous maintenance.
- 10:28SPEAKER_04: And this is the Astro study.
- 10:30SPEAKER_04: This is looking at subcutaneous gaselumab induction for ulcerative colitis, again on the top or bionaive, bottom or bioexperienced.
- 10:40SPEAKER_04: And interestingly, when you look just kind of visually at the bottom, subcutaneous, there's no drop-off, meaning using subcutaneous induction, and I'll ask my panelists whether they're using IV or sub Q for both ulcerative colitis and Crohn's induction, but you're seeing good efficacy with subcutaneous induction.
- 11:01SPEAKER_04: Now, subcutaneous induction is 400 milligrams, which is two times the 200 milligrams IV.
- 11:07SPEAKER_04: So just pharmacokinetically it's double, but it's still giving it zero, four, and eight weeks.
- 11:13SPEAKER_04: Mericizimab, also the data in ulcerative colitis, this is lucent one.
- 11:18SPEAKER_04: Merinchizimab you can see in blue, the dose is 300 milligrams.
- 11:23SPEAKER_04: Placebo in gray, and again you see a nice statistical efficacy, merinchizumab compared to placebo.
- 11:30SPEAKER_04: On the right side, an a priori endpoint was bowel urgency, and you can see kind of the separation of bowel urgency, meaning the improvement of bowel urgency as an endpoint with merinchiziumab over the first 12 weeks.
- 11:45SPEAKER_04: Maintenance with merenchumab for ulcerative colitis, the Lucent 2 study, and you can see again from left to right, and the blue compared to placebo, and again, we're seeing statistical efficacy of mericiziumab for the treatment of ulcerative colitis.
- 12:04SPEAKER_04: And then finally, risencissimab and ulcerative colitis, it's called the Inspire study.
- 12:09SPEAKER_04: And this, the purple is risen kissimab, the gray is placebo, the left-hand side is looking at the clinical response and remission rates at week 12, which are the primary endpoints.
- 12:21SPEAKER_04: And then you can see on the right hand side the ranked secondary endpoints, again, statistically significantly met with risen kissimab compared to placebo.
- 12:31SPEAKER_04: And then looking at the maintenance for ulcerative colitis with risen kissimab, similar theme.
- 12:37SPEAKER_04: For risen kissimab, as you know, there are two different maintenance dose options.
- 12:42SPEAKER_04: So on this slide, the light purple is 180 milligrams every eight weeks sub Q, now given as an on-body injector in clinical practice.
- 12:52SPEAKER_04: And the dark purple is risen kizimab 360 milligrams.
- 12:57SPEAKER_04: And you can see both of those were statistically significantly higher than placebo for most of these endpoints.
- 13:04SPEAKER_04: So before we pivot to Crohn's, and maybe Anita, I'll call on you first.
- 13:08SPEAKER_04: It's a lot of data, but your overall impression of ulcerative colitis, IL-23s, maybe start just to kind of give your thoughts on that.
- 13:18SPEAKER_08: Yeah, so I would say overall, these this the data is really great to see.
- 13:23SPEAKER_08: We're finally seeing numbers.
- 13:25SPEAKER_08: We've been talking for the longest time about hitting that therapeutic ceiling.
- 13:29SPEAKER_08: And now with this kind of endpoints, really stringent endpoints, both clinically as well as endoscopic, and we have histologic data for ulcerative colitis.
- 13:38SPEAKER_08: It's really uh great to see this level of efficacy and durability as well, uh, especially for ulcerative colitis.
- 13:47SPEAKER_08: I I also want to highlight, uh, Miguel, with the, for example, with the gazil command, we had the cohort, subcohort analyses, and these were also patients who were previously exposed to JAC inhibitors.
- 13:58SPEAKER_08: And and with the timing of when Gazil Comad was approved, we had more patients previously on a JAC inhibitor as well.
- 14:05SPEAKER_08: So this is very telling that we're seeing these type of efficacy results, even among patients who were previously exposed to a JAC.
- 14:13SPEAKER_04: Right.
- 14:13SPEAKER_04: So not just the naive patients, not just the previous biologic, but the JAC inhibitors.
- 14:18SPEAKER_04: Um, Ed, let me ask you a question about the subcutaneous.
- 14:22SPEAKER_04: So, you know, going back to, and I'll date myself, I came out of training in 1997, and Fliximab came out shortly after that, and we always thought you had to use IV therapy for induction.
- 14:35SPEAKER_04: IV was better than any other modality.
- 14:37SPEAKER_04: Yet for ulcerative colitis, we're seeing pretty good data in the Astros uh data with sub Q induction with Gasel QMAB.
- 14:44SPEAKER_04: One, I guess that does uh surprise you, and what are you doing in your own practice?
- 14:49SPEAKER_01: Yeah, so I would say it it is a little bit surprising because it's counterintuitive to what we think about ulcerative colitis, where we think about the mucosa being leaky, and in really sick patients think about acute severe ulcerative colitis coming in with a low albumin, and we're making a decision about are we even going to use an anti-TNF because they're losing protein across that barrier.
- 15:05SPEAKER_01: So I think it's a really good question.
- 15:07SPEAKER_01: The data would suggest, uh in terms of those clinical remission rates and the endoscopic endpoints that Anita mentioned, that you know, we're not supposed to compare study group to study group, but if you just think bar graph to bar graph, you're getting those same rates of remission at the same endpoint.
- 15:22SPEAKER_01: So I would say to answer your first question, yes, I think it is believable that we can achieve the same types of remission and the same type of outcomes that are sort of matched using a subcutaneous induction regimen.
- 15:34SPEAKER_01: And so to answer your question, the second part of it, we have transitioned to patients using Sub Q and UC as well for two reasons.
- 15:42SPEAKER_01: One, I think logistically, at least for us at UNC, it's hard to get patients into an infusion and to get them into an infusion in a rapid chair.
- 15:51SPEAKER_01: You have to go through the process of getting them a chair, getting the insurance approval.
- 15:54SPEAKER_01: I think that's a really important point.
- 15:56SPEAKER_01: And then secondly, you can know that your patient is leaving and when they're going to get on a drug, and that's that timely induction, as was mentioned on one of the first slides, is really important.
- 16:05SPEAKER_04: And then Angelina, I guess you know, for you see a lot of patients as an APP, they often come to you first and ask about safety and education around safety.
- 16:14SPEAKER_04: And although I showed it in the table, I didn't present it necessarily in the uh additional information.
- 16:20SPEAKER_04: But talk to us about, you know, you see Kenya Mab obviously was everybody knew that was very, very safe.
- 16:26SPEAKER_04: What about the IELT 23 class?
- 16:28SPEAKER_04: Anything additional?
- 16:29SPEAKER_04: And what are you actually telling your patients in the clinic?
- 16:32SPEAKER_09: Yeah, I it's a great question because you're right.
- 16:34SPEAKER_09: I mean, I like to pair the conversation of efficacy with safety at the same time, right?
- 16:38SPEAKER_09: You can't talk about one without the other.
- 16:40SPEAKER_09: Your patient's probably thinking more about safety up front, to be honest, in many ways, unless they're really sick, and that's the easiest of the conversations we could ever have, is with the super sick patient.
- 16:49SPEAKER_09: They're like, just make me feel better and I'm good.
- 16:52SPEAKER_09: But it's I think the safety conversation is quite easy, um, relatively speaking for the IL-23 entire class, right?
- 16:59SPEAKER_09: For those people who have been exposed to an IL-1223, I think it's particularly easy because you can say there's not really a difference in safety, with the exception that we're just gonna be monitoring, you know, for the medications, we need to be monitoring liver enzymes, right, for a patotoxicity.
- 17:14SPEAKER_09: So that may look a little bit different, but in reality, in my practice, it's actually I'm practicing the same way that I would have anyway.
- 17:20SPEAKER_09: I'm getting baseline labs at the beginning.
- 17:23SPEAKER_09: I am monitoring at a certain point to see that are the patients are responding anyway.
- 17:28SPEAKER_09: And I was doing this already, honestly.
- 17:30SPEAKER_09: They may not have understood what I was, you know, exactly the rationale that I was doing to check both are they are the labs looking better than they did initially, and also you're looking for the safety as well.
- 17:40SPEAKER_09: So that all really looks the same.
- 17:42SPEAKER_09: And to me, I feel equally reassured that the real things that matter, that there's not an increased risk for cancer, for example, I think that's really helpful.
- 17:49SPEAKER_09: There's not an increased risk for lymphoma, very helpful to be able to state that to your patient because that's they're worried about cancer.
- 17:57SPEAKER_09: And then the serious infection risk being very low, that reassures me and hopefully as well as the patient also.
- 18:02SPEAKER_04: Yeah, I think you and I practice very similarly, and I think the safety with these is excellent.
- 18:08SPEAKER_04: I think probably you as an audience that are using these see that.
- 18:12SPEAKER_04: I do the same thing uh pretty much with all of our therapies where I will do baseline, um, I usually get a CMP and CBC, but a baseline LFTs and an after induction.
- 18:22SPEAKER_04: I have in the IL23 class, as Angelina mentioned, seen some of these patients have a transient elevation in AST and ALT.
- 18:30SPEAKER_04: And if I see that after induction, I it does prompt me to not say let's wait six months to a year to get another set.
- 18:37SPEAKER_04: Probably within the next couple months we get another just to make sure that's not going up.
- 18:41SPEAKER_04: Before I go on, there are a couple of questions.
- 18:43SPEAKER_04: I'm gonna ask you first from our virtual audience, um, Anita, um, kind of the best candidate or positioning of the therapies.
- 18:51SPEAKER_04: The question was best candidate for Gaselcumab, but how do you position these three in ulcerative colitis?
- 18:57SPEAKER_04: And then Ed, there was a question about bowel urgency, which I mentioned with Miracizimab.
- 19:02SPEAKER_04: Is Mericizimab the only one that has that, or are there others?
- 19:05SPEAKER_04: So, Anita, you first in terms of positioning of the three.
- 19:09SPEAKER_04: Obviously, um they all look good.
- 19:11SPEAKER_04: How do you how do you decide?
- 19:13SPEAKER_08: Yeah, so overall, uh the the best candidate is the patient in front of you, and you have to look at their the factors are associated with that.
- 19:20SPEAKER_08: It comes down to several factors.
- 19:22SPEAKER_08: I think we're seeing efficacy here as outlined, but certainly recognizing that there becomes a patient preference.
- 19:29SPEAKER_08: We talked about the IV induction as well as the sub Q formulation.
- 19:34SPEAKER_08: And with Gazilcomab, it's the only IL-23 that allows a form that has the formulation of the sub Q.
- 19:40SPEAKER_08: For many of us, I'm I'm very fortunate to have an entire team work through that whole process for me.
- 19:46SPEAKER_08: So I don't deal with that stress.
- 19:48SPEAKER_08: But for the convenience factor of going through the authorizations for getting the IV and then the sub Q and all of this, it's probably that easy button, Miguel, that I think that it's also not only the patient preference, but potentially also the prescriber preference to have that easy button.
- 20:04SPEAKER_08: You want to start an IL23 and you want the convenience factor as well.
- 20:08SPEAKER_04: Yeah.
- 20:08SPEAKER_04: So the take-home from Dr.
- 20:09SPEAKER_04: Aspaly is the easy button.
- 20:12SPEAKER_04: And quote, I don't deal with that stress.
- 20:14SPEAKER_03: Yeah.
- 20:15SPEAKER_04: I can't have wrinkles.
- 20:17SPEAKER_04: Come on.
- 20:19SPEAKER_04: That's a take-home for me.
- 20:20SPEAKER_04: All right.
- 20:21SPEAKER_04: Uh um, Ed, let me ask you a quick question, then we'll we'll go on.
- 20:25SPEAKER_04: Bow urgency, Americ showed the data.
- 20:28SPEAKER_04: Um, do the others have that?
- 20:30SPEAKER_04: Maybe speak to that.
- 20:31SPEAKER_01: Yeah, so I think it's a great question because bowel urgency is among the, if not the most critical symptom that your patients will have.
- 20:38SPEAKER_01: And I think the reason that the mirakizimab data is really important is because if you're like me in clinic, you can talk to your patients about do you have bow urgency?
- 20:46SPEAKER_01: And they don't say, yes, my urgency numeric rating score, which I'll tell you in a second, is a seven.
- 20:51SPEAKER_01: They say I can't make it through a meeting or I can't make it through my commute.
- 20:54SPEAKER_01: And so we now have a way to quantify that through the Mirakizimab trial program.
- 20:58SPEAKER_01: So Miguel showed you that curve that fell off compared to placebo, and so that was the urgency NRS.
- 21:04SPEAKER_01: And so that's why I think you saw that rapid drop in urgency.
- 21:08SPEAKER_01: So that's something that's really important to know about Mirakizimab.
- 21:11SPEAKER_01: But that's not the only even IL-23 that has data for urgency.
- 21:14SPEAKER_01: Hidden in one of the other bar graphs on the Risen Kisimab, you saw a large improvement in patient-reported urgency scores as well in the Risen Kisimab data.
- 21:23SPEAKER_01: So I think probably a lot of our therapies uh will help urgency because they're helping the patient's symptoms of ulcerative colitis.
- 21:29SPEAKER_01: But I think the MirakisMab program did a really nice way of quantifying this so that we can track it over time and not have to ask some of these questions that are really important to patients, but then we can quantify it in a clinical trial program.
- 21:41SPEAKER_04: Yeah, I think the Merin Kizimab had a numeric score that was developed and they implemented it a priori as an endpoint.
- 21:49SPEAKER_04: Just to be clear, as Ed said, the other IEL 23s have either post hoc data or data that do show improvement in bowel urgency.
- 21:58SPEAKER_04: So it's not maybe specific to.
- 22:00SPEAKER_04: The aisle 23 Marin Kizzy Mab improving urgency.
- 22:03SPEAKER_04: It was measured a priori, which I think was really good well done, but probably all of them do that.
- 22:09SPEAKER_04: All right, let's um uh finish out the didactic presentation.
- 22:13SPEAKER_04: And Anita, when we get to the end of this, I'll talk to you because I know you're one of the primary authors on Galaxy.
- 22:20SPEAKER_04: So this is now we're switching to Crohn's disease, and this is Gaselculab induction in Crohn's.
- 22:25SPEAKER_04: Um I'm gonna point out two things here.
- 22:27SPEAKER_04: You'll see different induction doses with the different colors of red.
- 22:33SPEAKER_04: Um, I will say that the light pink is the 200 milligram, which is FDA approved, but you can see the higher doses didn't have any additional improvements.
- 22:45SPEAKER_04: So this is why the FDA chose the 200 milligram, which is what we use for IV induction of Crohn's.
- 22:52SPEAKER_04: The other thing you'll notice that's built into the study, which I think is unique, is it is a head-to-head gaselcumab, and the green bar on the right-hand side is with Eustakinumab.
- 23:02SPEAKER_04: So built into the study is not just placebo, but really looking at a head-to-head with Eustakinumab.
- 23:09SPEAKER_04: So this is Galaxy 2 and 3 now looking at the maintenance in Crohn's disease.
- 23:14SPEAKER_04: And again, the reason there's the light uh pink and the dark is that's the two different doses for maintenance of 100 milligrams every eight weeks or 200 milligrams every four weeks.
- 23:25SPEAKER_04: And there's not placebo on this.
- 23:27SPEAKER_04: This is the green bar is Eustakinumab.
- 23:30SPEAKER_04: And at the end I'll ask you to comment, Anita, but we are seeing statistical benefit and efficacy of gasel cumab, not just over placebo, but an IL-1223 Eustakinumab.
- 23:44SPEAKER_04: Now we like Astro, sub Q for ulcerative colitis, gravity, sub Q induction for Crohn's disease, and a very similar theme to what we just talked about in ulcerative colitis, the sub Q induction we did see statistically efficacy for clinical remission and endoscopic response, independent of bio-naive, which are the middle sets of bars, or bioIR, so patients who had been on biologic therapy and seeing these nice deltas.
- 24:14SPEAKER_04: Similarly, if you use subcutaneous induction in the gravity and then you carry it out to week 48, you are seeing fairly large separation.
- 24:24SPEAKER_04: If you look at the placebo responses here, very low, but quite a delta compared to Gasel QMab.
- 24:32SPEAKER_04: So the sub Q for Crohn's disease induction, as we talked about for ulcerative clitis, we're seeing benefit and efficacy with that.
- 24:40SPEAKER_04: Vivid 1, now we're looking at the Merinchizimab induction and Crohn's disease.
- 24:45SPEAKER_04: You can see the blue is Merinchizimab, the gray is placebo.
- 24:50SPEAKER_04: This is the week 12 data, and you can see clinical response by PRO, endoscopic remission, and clinical remission.
- 24:57SPEAKER_04: Again, statistical endpoints were met.
- 25:00SPEAKER_04: These are the maintenance data with merinchizimab and Crohn's disease.
- 25:04SPEAKER_04: Also at week 52, the endpoints were met.
- 25:08SPEAKER_04: Now, in this in one of the studies, VIVID1, one of the secondary endpoints was comparing Mericismab to Eustachiniumab.
- 25:16SPEAKER_04: Eustakinumab here is in green.
- 25:18SPEAKER_04: And I think you you can see something different than what we saw with gaselcumab, in that we're not seeing a statistically higher benefit or efficacy of merinchismab versus eustacinumab.
- 25:30SPEAKER_04: The bars look very similar.
- 25:32SPEAKER_04: Some of that has to do with the methodology, the way the study was designed, but we did see a separation with Gaselcumab and Eustachiniumab.
- 25:40SPEAKER_04: We are not seeing that with merinchismab and eustachiniumab.
- 25:44SPEAKER_04: So now risenchimab induction in Crohn's, advance and motivate.
- 25:49SPEAKER_04: It's just the patient population in advance was a mixed population, meaning some were bio naive, some were biofailure.
- 25:57SPEAKER_04: Motivate on the right hand side is all biofailure.
- 26:00SPEAKER_04: And again, you're seeing statistically higher rates with risenkissimab compared to placebo.
- 26:06SPEAKER_04: This is looking at side-by-side clinical remission and endoscopic response, with the theme and the message that we're seeing good not only clinical remission, but also endoscopic response with risen kissimab in Crohn's disease.
- 26:22SPEAKER_04: And then finally, Risen Kissimab did have a comparator trial sequence with Eustachiniumab.
- 26:29SPEAKER_04: And as I mentioned with Gaselcumab, although this trial was designed a bit differently, and Galaxy did build in an arm of Eustakinumab.
- 26:38SPEAKER_04: But nonetheless, Risen Kissimab compared to Eustakinumab, you do see a separation and an efficacy benefit with Risen Kissimab compared to Eustakinumab.
- 26:49SPEAKER_04: So before we get to the cases, and this will be the remainder of our next uh hour to hour and a half, I I want to ask you, Anita, in terms of the Galaxy study, and I know you were involved in that, kind of maybe high-level comments.
- 27:04SPEAKER_04: We talked about the built-in arm with Eustachiniumab.
- 27:07SPEAKER_04: Any observations you want to share?
- 27:09SPEAKER_08: Yeah, so with the Galaxy study, we were able to have the a treat-through design, which in other words says no matter what the medication the patient was started on at the start of the study, they continued on with that.
- 27:23SPEAKER_08: And so that really allows more of that real world, if you if we can use that, this is the real world, actual clinical practice of what happens when a patient gets started on gazilkinab or use to kinemab or is on placebo, right?
- 27:35SPEAKER_08: So that was very telling for us.
- 27:37SPEAKER_08: Also, the doses, as you highlighted, Miguel, uh, overall you could see that they both doses, 100 milligrams or the 200 milligrams, we were able to see efficacy at, again, high percentages that typically we don't have we have not seen previously.
- 27:55SPEAKER_08: Having that active comparator with Eustakinemat was very informative.
- 27:59SPEAKER_08: Sequence, as you alluded to, was designed differently, but incorporating Eustakinemab into the galaxy allowed us to do several post hoc analyses, of which we've presented at many of the major congresses, and uh it's it's manuscript in process.
- 28:14SPEAKER_08: Um, so so that's coming here at a theater near you.
- 28:17SPEAKER_08: Um so it'll allow you to be able to, it allowed us to perform an analysis, Miguel, where we said, what about the patient who initially received Eustakinomab and then lost a response or didn't have a response?
- 28:30SPEAKER_08: Now can we perform our analyses of when we switch them to gazilchimab, what happens?
- 28:35SPEAKER_08: And what we actually found was once we switched them to gazilchemat, and this was without an IV induction, we went straight to the sub Q.
- 28:43SPEAKER_08: We switched them to 200 milligrams subq of gazilcomap, previously been exposed to use dechinemat, and we found that the efficacy, durability, rapidity by all those endpoints were comparable to as if a patient was in that cohort of bio-exposed and then received gazilkymap.
- 29:02SPEAKER_08: So that's very telling for us, an answer that sequence was unable to give us.
- 29:06SPEAKER_04: Yeah, and I think so really important data that I didn't present that I think you presented that the European, one of the European meetings, is that you the question comes up if a patient's been on Eustachiniumab and failed or lost response, can use an IL-23, and we do have efficacy data with Gascelchiumab that it didn't present.
- 29:26SPEAKER_04: Um, Angelina, let me ask you a uh a question about the sub Q induction with Crohn's, kind of similar to ulcerative colitis.
- 29:34SPEAKER_04: Uh maybe the answer is gonna be identical.
- 29:37SPEAKER_04: Are you using IV Gascelchiumab in Crohn's induction, or you've really switched over to sub Q?
- 29:43SPEAKER_04: What is that looking like in your practice?
- 29:46SPEAKER_09: Honestly, this has to do a bit with patient preference and what is gonna be easiest for the patient to do.
- 29:51SPEAKER_09: I've been surprised, I thought everyone's gonna want sub Q.
- 29:54SPEAKER_09: Like, why would you want to go into an infusion center for IV?
- 29:57SPEAKER_09: But in fact, I've had some patients that have really said, I want, I'm used to that.
- 30:02SPEAKER_09: They're used to being monitored and having an IV.
- 30:05SPEAKER_09: But I will say the majority of my patients are now going, I'm going with sub Q induction.
- 30:09SPEAKER_09: It really is uh shortening the time to medication when you can use the sub Q induction compared to IV.
- 30:16SPEAKER_09: So you don't you're not just waiting for insurance authorization.
- 30:19SPEAKER_09: And then to Ed's point, like finding a chair and getting your patient scheduled, the sub Q does really uh get the drug to patient faster.
- 30:26SPEAKER_04: Yeah, I agree.
- 30:26SPEAKER_04: I mean, I think most of my patients, you're right, there might be a rare exception.
- 30:31SPEAKER_04: Most of my patients were using sub Q induction with Gaselculab for both Crohn's and ulcerpclitis.
- 30:36SPEAKER_04: There might be a rare, rare, rare exception.
- 30:39SPEAKER_04: Ed, there was a question that came in, and then we'll um start with the cases.
- 30:43SPEAKER_04: The higher doses of IL-23, are they related to side effects?
- 30:48SPEAKER_04: So the the question was specifically: I showed the doses of gaselcumab that were done, and the 200 milligram had the higher efficacy, but there were even higher doses that didn't show any benefit.
- 31:00SPEAKER_04: But for risen kizumab and gaselumab in maintenance, we do have two doses, a lower and a higher.
- 31:06SPEAKER_04: Um, higher, maybe we get some efficacy benefit, but then is that a trade-off or are we seeing safety problems with the higher doses?
- 31:14SPEAKER_01: Yeah, that's a great question.
- 31:15SPEAKER_01: I would say um, contrary to what we see in some other mechanisms of action, we don't see that.
- 31:21SPEAKER_01: Um and and just to be very clear about what I'm talking about, when we see induction doses with JAC inhibitors, for instance, I think we tend to see more shingles risk, more infectious risk when we have the high dose compared to like when we go down to the lower dose for maintenance.
- 31:33SPEAKER_01: We don't see that with the higher dose of IL-23 that I'm aware of.
- 31:37SPEAKER_01: I any of the panelists you know know that data better than me, definitely correct me.
- 31:41SPEAKER_01: But I don't think we've seen that with the IL-23s.
- 31:43SPEAKER_04: Yeah, so I think one of the nice things, and just a take-home point, sometimes people say, Well, I don't want to use the higher dose of Risen Kizimab or GaselkiMab in maintenance because I'm worried we talked about the liver or some other potential side effects.
- 31:56SPEAKER_04: We are not seeing a safety trade-off.
- 31:58SPEAKER_04: So the nice thing with this is we're not seeing a safety ceiling, meaning higher doses don't equate to worse safety.
- 32:06SPEAKER_04: So generally in my practice, and I realize I have a referral bias at Cleveland Clinic where I might have a sicker patient, I am using the higher doses in maintenance for both Gasel QMab, 200 every four weeks, and for Risen Kizimab, the 360 every eight weeks.
- 32:22SPEAKER_04: The data on the lower doses and maintenance for both of those look quite good.
- 32:26SPEAKER_04: So I don't want the take-home to be you have to use the higher dose, but we are not seeing a safety trade-off with that.
- 32:33SPEAKER_04: All right, so let's dive into our patients.
- 32:35SPEAKER_04: Um, first of all, get ready because as an audience, I'm gonna present the case and then we're gonna ask you all first what you would do in terms of the multiple choice options uh for therapy.
- 32:48SPEAKER_04: So this is a real patient.
- 32:50SPEAKER_04: Some of you may have seen Natalie at some of our meetings.
- 32:53SPEAKER_04: She's also a patient advocate.
- 32:55SPEAKER_04: She's 42, long-standing Crohn's ileitis.
- 32:58SPEAKER_04: She's had this since 21.
- 32:59SPEAKER_04: She now has worsening symptoms that you can see there.
- 33:03SPEAKER_04: She's actually been in a long-term remission with Adolibiumab, and there was a payer-mandated switch to Adolibiumab biosimilar.
- 33:12SPEAKER_04: And she felt not only that she was frustrated, but she felt that she also started to get more symptoms.
- 33:18SPEAKER_04: One very quick editorial comment.
- 33:20SPEAKER_04: We've not seen a difference in terms of efficacy in biosimilars compared to the innovator product, and I want to make it very clear.
- 33:28SPEAKER_04: I am personally comfortable with the biosimilars.
- 33:31SPEAKER_04: However, we do have patients like Natalie who tell us, and it might be more than even the nocebo, and then we can get into whether we check levels.
- 33:39SPEAKER_04: Nonetheless, she started to have more symptoms.
- 33:43SPEAKER_04: Um, and now she's saying, okay, I've been on Adolibia Mab every two weeks and doesn't want to be on an IV therapy.
- 33:50SPEAKER_04: And oh, by the way, in the very bottom right of this is something that you may see in your patients in TNF.
- 33:56SPEAKER_04: She's noticing that she's starting, it's not terrible, but she's starting to get the cereoform reaction and the umbolicus around the ears and the scalp.
- 34:05SPEAKER_04: I tell my fellows, if you examine patients on TNF inhibitors, patients will say, I got a I have a little dryness in my belly button.
- 34:12SPEAKER_04: That's probably actually a cereoform reaction in TNF.
- 34:16SPEAKER_04: Usually it's very mild, you don't have to do anything about it, but she's starting to get it in her scalp and her ears.
- 34:20SPEAKER_04: You can see that based on objective data, CRP, fecal coppertectin, she has elevation.
- 34:26SPEAKER_04: Importantly, is the third bullet point.
- 34:28SPEAKER_04: An adelibium ab trough level was measured.
- 34:31SPEAKER_04: It was 19, which would represent what I would consider an optimal trough level, and she has no antibodies.
- 34:39SPEAKER_04: And you can see her hemoglobin platelets.
- 34:41SPEAKER_04: Her album is 3.5, it's on the low end of normal, but it's not abnormal.
- 34:46SPEAKER_04: All right, so here is where all of you come in.
- 34:49SPEAKER_04: What would you do next?
- 35:18SPEAKER_04: So switch to NIL23.
- 35:20SPEAKER_04: Some say go ahead and switch to veto, some said switch to eupatocinib, and some said give her a little bit of butesinae and see how she does.
- 35:28SPEAKER_04: Before I get to the community gastroenterologists and how they answered, um, Ed, anything surprising here or anything, any comments you would want to make?
- 35:38SPEAKER_01: Yeah, so I think it's it's a little bit interesting that we have, you know, we have a smattering, we have at least one answer to each one.
- 35:45SPEAKER_01: And I think that that's really shows you what you said.
- 35:47SPEAKER_01: There's maybe not one right answer.
- 35:48SPEAKER_01: So people can think about this in a little bit different way.
- 35:51SPEAKER_01: I think it when I think through this case and sort of how how this case is progressing, I think the storaform rash is the thing that stands out to me the most.
- 35:58SPEAKER_01: The disease activity we could probably tackle in a in a couple of different ways.
- 36:01SPEAKER_01: But in my experience, when you have a serious form rash, especially to the anti-TNF, that is not likely to respond to another anti-TNF.
- 36:09SPEAKER_01: In fact, it's the anti-TNF will probably drive that same reaction again.
- 36:13SPEAKER_01: And knowing now that we have so many different mechanisms that of action that we could use as seen by this screen, an IL-23 works really, really well in this situation, and IL-1223 also works really well in this situation.
- 36:24SPEAKER_01: But we talked about some of that head-to-head data.
- 36:26SPEAKER_01: So I think an IL-23 would probably be my go-to initial decision, you know, um in this particular situation.
- 36:32SPEAKER_04: Angelina, let me ask that a little bit differently.
- 36:34SPEAKER_04: Are any of these choices one that you would not do where you would look at and say, you know, that's not a great idea?
- 36:40SPEAKER_09: Yeah, that's a that's a good way of looking at it too, because I call that the back door.
- 36:44SPEAKER_09: Like instead of sometimes when you're like, there's multiple good answers, but like what is not an awesome answer?
- 36:50SPEAKER_09: Um I probably I think of a 19, uh trough level of atolimimab 19 as being a ther within the therapeutic range.
- 36:58SPEAKER_09: Um, you know, so that's not necessarily I don't think going too weakly is going to benefit the patient in the sense of symptom control, and also because of the sarizoform rash, that was well, I agree completely on that, that once you start seeing that, it is it's likely to worsen over time, um, maybe starting off mild.
- 37:17SPEAKER_09: But once really, if you've seen this before, to Miguel's point, it's one thing if it's in a belly button, which is hideable, which you can, you don't have to show that.
- 37:28SPEAKER_09: Once you start getting it in the ears and then around the scalp, if you've ever seen severe cases of this, it is debilitating.
- 37:35SPEAKER_09: I have had people, when you start getting in the scalp, people will start losing their hair.
- 37:39SPEAKER_09: It can be really awful and almost to the point where people are really not wanting to even leave the house.
- 37:45SPEAKER_09: So I do take the sarice farm rashes pretty seriously.
- 37:49SPEAKER_09: The topicals are okay if you're like, you know, dabbling in it, but it can become really messy really fast.
- 37:54SPEAKER_09: So, long story short, I really would think about that, you know, between the anti-TNF would not be I a selection I would do because the trough is good, switching to another anti-TNF agent as Ed already mentioned, it is likely to continue this issue as we go on.
- 38:11SPEAKER_09: So those were the easy throuts for me.
- 38:13SPEAKER_04: Yeah, so I think the the the take-home is if you dabble in it and it helps the mild psoriasis, that's okay.
- 38:19SPEAKER_04: Like the dabbling comment.
- 38:21SPEAKER_04: Um, but it but we do worry about the scalp.
- 38:24SPEAKER_04: Um, Anita, question is she's a newscaster.
- 38:27SPEAKER_04: Um now I'm gonna ask you which of the three aisle 23.
- 38:30SPEAKER_04: She's a newscaster, you kind of heard some of her preferences up front.
- 38:34SPEAKER_04: Maybe this is self-evident, but which of the three would you lean toward?
- 38:38SPEAKER_08: Again, the convenience factor, right?
- 38:40SPEAKER_08: And so with that, uh being able to have these sub Q formulations seems to be the most palatable probably for her, as well as with that easy button we talked about, right?
- 38:51SPEAKER_04: Yeah, and I think also obviously she is cognizant of um, she is a public figure, she doesn't want to go in an IV infusion, so there's that as well.
- 38:59SPEAKER_04: All right, so let's go forward.
- 39:02SPEAKER_04: Um This is going to be cool because now you're gonna hear if you can play the audio, you can read the screen, but let's hear what a community gastroenterologist said about Natalie.
- 39:15SPEAKER_02: The patient has been on Adolimomab or it's biosimilar for some time, but she has had a flair requiring steroid rescue.
- 39:23SPEAKER_02: Her disease level is at least moderate, including constitutional symptoms of anemia.
- 39:28SPEAKER_02: She also has elevated biomarkers.
- 39:31SPEAKER_02: I feel it is time to change to a different class of advanced therapy, and an IL-23 has unsurpassed efficacy, a better safety profile than upatocytonib, and should be efficacious in psoriasis should she prove to have that.
- 39:48SPEAKER_02: But Elizabeth would likely be less efficacious, but an acceptable choice if she has any relevant conditions that would make a more gut-specific agent preferable.
- 40:00SPEAKER_02: Also, a subcutaneous route of administration would be preferable given her social circumstances.
- 40:07SPEAKER_04: So, how about a rural gastroenterologist?
- 40:11SPEAKER_02: I would increase dosing frequency of her current atolimomab therapy.
- 40:15SPEAKER_02: She was in long-term remission on Adolimomab and has only been symptomatic for six to eight weeks.
- 40:21SPEAKER_02: The only major change was a payer-mandated biosimilar switch three months ago.
- 40:26SPEAKER_02: Before I start chasing newer agents, I want to try the most practical, familiar, and insurance-friendly step first.
- 40:35SPEAKER_02: If this is for macrokinetic loss of response after the switch, dose escalation is a reasonable move and often easier to get approved than a full therapy change.
- 40:45SPEAKER_02: I'm also not ready to assume she needs a whole new mechanism yet.
- 40:50SPEAKER_02: I would check TROF and antibody levels, rule out C diff, and recheck CRP and FCP.
- 40:58SPEAKER_02: I wouldn't switch to another anti-TNF agent unless she has antibodies or true secondary loss of response.
- 41:06SPEAKER_02: Switching within class is a big step and often difficult with insurance.
- 41:13SPEAKER_02: I wouldn't switch to an IL-23 inhibitor.
- 41:16SPEAKER_02: I know the data look good, but I'm still cautious with newer therapies.
- 41:20SPEAKER_02: I want more real-world durability and long-term safety experience before making that my go-to, especially when she did well for years on anti-TNF.
- 41:32SPEAKER_02: It may be fine, but I don't want to be the first one in my zip code to find out it's not.
- 41:39SPEAKER_02: I wouldn't switch to Vetalismab.
- 41:42SPEAKER_02: It's safe, but it's an infusion, and she specifically wants to avoid IV therapy.
- 41:48SPEAKER_02: Also, it may take longer to kick in, and she's already flaring.
- 41:54SPEAKER_02: I wouldn't switch to patocyinid.
- 41:56SPEAKER_02: It is effective, but it's a systemic jack inhibitor.
- 42:00SPEAKER_02: I'm not reaching for that unless I really have to.
- 42:03SPEAKER_02: More monitoring, more safety baggage, and it's not my first move in someone who was stable for years.
- 42:11SPEAKER_02: And I wouldn't use budastinide.
- 42:13SPEAKER_02: She's already needed steroids and is still symptomatic.
- 42:17SPEAKER_02: That's how patients slowly drift into chronic steroid dependence while the disease keeps simmering.
- 42:25SPEAKER_04: So it's interesting.
- 42:26SPEAKER_04: Some of you in the audience did say you would go to Adalimimab weekly.
- 42:31SPEAKER_04: So this is where you are hearing variations.
- 42:34SPEAKER_04: Let's hear from the community and then I'll show you some other responses.
- 42:39SPEAKER_02: I would switch to an IL-23 inhibitor.
- 42:42SPEAKER_02: She had long-term remission on Adelimumab, then had a payer-mandated biosimilar switch, and within three months she's flaring again and already needed butecenide rescue.
- 42:54SPEAKER_02: That's a signal this isn't just a bad week.
- 42:57SPEAKER_02: This is loss of control.
- 42:59SPEAKER_02: What really pushes me towards switching mechanisms is the new and worsening psoriform rash affecting the umbilicus, ears, and scalp.
- 43:08SPEAKER_02: That's consistent with paradoxical psoriasis from anti-TNF exposure, and I'm not going to fix that by doubling down on the same class.
- 43:18SPEAKER_02: I would pick UsauMab because it offers sub-Q dosing and she wants to avoid IVs and time away from work.
- 43:26SPEAKER_02: And it supports durable steroid-free control.
- 43:31SPEAKER_02: Increasing the dosing frequency of her current adolymumab therapy could work if this were purely low drug exposure.
- 43:40SPEAKER_02: But the rash makes me think she's developing a class related problem.
- 43:44SPEAKER_02: I'm not optimizing a drug that's also causing a new inflammatory skin issue.
- 43:51SPEAKER_02: If she had antibodies or injection issues, maybe I would switch to another anti TNF agent.
- 43:58SPEAKER_02: But paradoxical psoriasis often.
- 44:01SPEAKER_02: I'd rather pivot mechanisms than keep rolling the anti-TNF dice.
- 44:07SPEAKER_02: Switching to vetalizamab is effective and safe, but it's IV-based and she's trying to avoid infusions.
- 44:14SPEAKER_02: Also, it won't help the rash.
- 44:18SPEAKER_02: Switching to upatocyt nib offers strong efficacy and oral convenience, but I typically use this after biologic failure or when I need speed.
- 44:29SPEAKER_02: Here, IL-23 gives me durability and skin benefit with a cleaner long-term comfort level.
- 44:38SPEAKER_02: I wouldn't manage symptoms with butesinide and then reevaluate in three months.
- 44:43SPEAKER_02: That's how steroid dependence starts.
- 44:46SPEAKER_02: She's already showing she needs escalation.
- 44:50SPEAKER_04: Alright, so you're hearing some themes.
- 44:52SPEAKER_04: I'm not going to play these, but a few other people said they would switch to aisle 23.
- 44:57SPEAKER_04: There was somebody because she had been on TNF, you padded a synonym.
- 45:01SPEAKER_04: And I think we're hearing themes of as what we're saying would probably be things we wouldn't do.
- 45:06SPEAKER_04: So certainly B.
- 45:07SPEAKER_04: Dust and I think everybody agrees.
- 45:09SPEAKER_04: Let's hear from Millie Long what she said.
- 45:14SPEAKER_05: Hi, my name is Millie Long.
- 45:16SPEAKER_05: I'm a professor of medicine and chief of the Division of Gastreneurology at University of North Carolina at Chapel Hill.
- 45:22SPEAKER_05: And here I specialize in the management of inflammatory bowel disease.
- 45:26SPEAKER_05: So to start things off, I'd like to discuss case number one, Natalie.
- 45:31SPEAKER_05: So my answer for what to do in Natalie's care is actually option C: switch to an IL-23 inhibitor.
- 45:38SPEAKER_05: And let me tell you why.
- 45:40SPEAKER_05: So Natalie has Crohn's disease.
- 45:43SPEAKER_05: She's 42 years old.
- 45:44SPEAKER_05: She has been on aduluminum.
- 45:47SPEAKER_05: And importantly, she has had a recent level checked, which was therapeutic.
- 45:51SPEAKER_05: It's at 19.
- 45:52SPEAKER_05: And also in her clinical history, she actually has started to report a mild psoriasiform rash.
- 45:59SPEAKER_05: And this is kind of around her umbolycus and behind her ears.
- 46:03SPEAKER_05: And so what this is is most likely an anti-TNF-induced kind of psoriasoform eruption.
- 46:10SPEAKER_05: So interestingly, you can see some of these paradoxical reactions on anti-TNF.
- 46:15SPEAKER_05: And recently in the literature, it's actually been shown that an IL-23 receptor abnormality, a genetic abnormality, is actually associated with this.
- 46:25SPEAKER_05: And so the IL-23s are the best agent to manage this psoriasoform eruption.
- 46:30SPEAKER_05: Importantly, it also is an agent that has shown great efficacy in Crohn's disease in individuals who've previously been exposed to an anti-TNF.
- 46:38SPEAKER_05: And she not only has been exposed, but she has had a mechanistic failure of that anti-TNF.
- 46:44SPEAKER_05: A couple of other pearls, remember that we never go on symptoms alone, and she did have objective workup of her symptoms where she had an elevated fecal cow protectin.
- 46:54SPEAKER_05: And importantly, a colonoscopy with an SESCD of 11, really markedly involving the ilium.
- 47:00SPEAKER_05: And that's a very high SES CD if someone has isolated ileal disease.
- 47:04SPEAKER_05: So she actually has quite severe disease.
- 47:06SPEAKER_05: We we need to get our best foot forward.
- 47:11SPEAKER_04: So one thing we wanted to show you is this.
- 47:40SPEAKER_04: So this is really something, and Millie mentioned the very last bullet point on this slide, which I think is interesting, that this may actually be one of our predictive markers, the IL-23 receptor gene.
- 47:50SPEAKER_04: It's not something we can necessarily measure in clinical practice yet, but usually these patients do quite well with uh IL-23.
- 47:57SPEAKER_04: We're going to hear now from Jessica Allegretti and then uh Ed Loftus, and then we'll move forward.
- 48:03SPEAKER_07: Hi everyone, my name is Jessica Allegretti, and I'm the medical director of the Crumbson Colitis Center at the Brigman Women's Hospital in Boston.
- 48:10SPEAKER_07: And for case number one, I would choose C switch to an IL-23 inhibitor, and that's for several reasons.
- 48:17SPEAKER_07: Here we have a young woman who has experienced secondary loss of response to an anti-TMF.
- 48:22SPEAKER_07: We know she has a good drug level, she has not developed antibodies to the drug, so really we want to move out of class to a new mechanism of action.
- 48:32SPEAKER_07: We also note that she has a preference towards sub Q injections over IV infusions, and we know that there are agents within the IL-23 class which are entirely sub Q or even mainly sub Q with an IV load.
- 48:45SPEAKER_07: So I think there's a lot of flexibility there.
- 48:47SPEAKER_07: We also note that this patient has a psoriform rash, and we know that IL-23 inhibitors also concurrently treat psoriasis and are approved for that indication as well.
- 48:58SPEAKER_07: So I think overall that's going to be a great choice for this patient.
- 49:11SPEAKER_00: Hello, I'm Ed Loftus.
- 49:13SPEAKER_00: I'm a professor of medicine at Mayo Clinic in Rochester, Minnesota, and I am not a Pittsburgh Steelers fan.
- 49:20SPEAKER_00: Um and uh regarding the first case, this is um a case of somebody who you know switched to an atelemyc bio similar, their symptoms have been worsening, they're getting a little bit of a psoriasoform reaction, they have a therapeutic trough level, no antibodies.
- 49:41SPEAKER_00: Um we have objective evidence of inflammation as manifested by the fecal cow and the colonoscopy.
- 49:49SPEAKER_00: So this patient does need to switch therapies.
- 49:52SPEAKER_00: I probably would not go with an anti-TNF because the psoriasiform reaction that'll happen with the next one.
- 49:59SPEAKER_00: Um, I do like the option of an IL-23 inhibitor here.
- 50:05SPEAKER_00: Um, I think IL-23 inhibitors work particularly well in this sort of anti-TNF failure um setting.
- 50:14SPEAKER_00: And for this particular patient, because uh she's expressed a desire for uh subcutaneous therapy, um I mean I I I'd probably be leaning towards Guselchiumab.
- 50:28SPEAKER_00: I I suppose you could also consider the other two um anti-interleukin 23 inhibitors, although you know the initial doses would be IV, although that would be a limited period of time.
- 50:42SPEAKER_00: So for all those reasons, I'd be probably picking an anti-interleukin here.
- 50:49SPEAKER_04: Right.
- 50:49SPEAKER_04: We did put this through Chat GBT, um, and kind of just in the effort of time, uh, since you heard already the digital voices, it chose aisle 23.
- 51:00SPEAKER_04: I will tell you that um the next case has much more variability.
- 51:05SPEAKER_04: I think this one was a kind of an easy starter case.
- 51:09SPEAKER_04: Um, but let's hear from uh Natalie kind of directly her thoughts.
- 51:16SPEAKER_10: My name is Natalie Hayden.
- 51:17SPEAKER_10: I'm 42 years old.
- 51:18SPEAKER_10: I was diagnosed with Crohn's disease at age 21.
- 51:21SPEAKER_10: I have three kids, ages eight, six, and four.
- 51:24SPEAKER_10: I'm a former TV news anchor and reporter, and I blog at lightscameracrohnes.com.
- 51:30SPEAKER_10: My senior year of college, I went on spring break to the Bahamas, and I'll never forget the abdominal pain that I felt.
- 51:37SPEAKER_10: And in the moment, it was the first time I ever dealt with something like this.
- 51:41SPEAKER_10: Fast forward to May, where when I graduated from our commit, my symptoms really started to persist.
- 51:47SPEAKER_10: I'm talking about fevers of up to 104 on multiple occasions and then horrible chills.
- 51:53SPEAKER_10: So I went into this not even knowing what was wrong with me.
- 51:57SPEAKER_10: And they did a rectal exam and they did a CT of my abdomen.
- 52:01SPEAKER_10: And I kind of blacked out in the moment, honestly, because I don't know how I reacted when the doctor walked in the room and he said, You have Crohn's disease, you are malnourished, you're dehydrated, you're getting hospitalized immediately, and you're doing a colonoscopy in the morning to confirm this.
- 52:17SPEAKER_10: And my world came crashing down.
- 52:19SPEAKER_10: I went from being a perfectly healthy, self-sufficient, driven, ambitious 21-year-old who had the world by the tail, who planned to work in TV news and take it by storm, to somebody who was hospitalized for a week having to do a colonoscopy.
- 52:35SPEAKER_03: And then in terms of her quality of life.
- 52:40SPEAKER_10: So when you have IBD, you don't know what the next hour brings.
- 52:42SPEAKER_10: You don't know what the next day brings.
- 52:43SPEAKER_10: Yes, you might be in remission today, but what about tomorrow?
- 52:46SPEAKER_10: And I think that I think that's something so many patients and caregivers struggle with is the unpredictability and is such a challenge with this disease.
- 52:54SPEAKER_10: We can think we have it under control.
- 52:55SPEAKER_10: We can think the treatment and therapy is working, we can say the scope looks clean, we can say the labs look like they're on target, but then all of a sudden, something could happen the next day.
- 53:04SPEAKER_10: So um that's been a struggle even 20 years in.
- 53:08SPEAKER_04: So I think you know it's important to hear um the patient voice in this, and and we really appreciate Natalie um being vulnerable to share her story.
- 53:17SPEAKER_04: And I think this also puts it in perspective some of how we need to interact with patients.
- 53:22SPEAKER_04: Now, just coming to the end of this case one, before we get to case two, this is kind of the table scorecard of what was discussed.
- 53:31SPEAKER_04: And I think the majority of people, and then AI, also picked aisle 23, but a couple said increase the adolybnium map, somebody said you pad a synonym, which by the way, I don't know was necessarily been wrong.
- 53:44SPEAKER_04: Um, um, it's just the aisle 23 in terms of some of the safety, the efficacy, would probably been what I would have gone with as well.
- 53:52SPEAKER_04: And I think some pearls from this case, and then we're gonna ask all of you again uh if you changed your mind or changed your decision one way or the other.
- 54:01SPEAKER_04: Um but we talked about the psoriform reaction, we talked about some of the ACG actually put this in their guidelines in terms of prior intolerance to therapies, safety profile, uh, life stage considerations, um, and then this idea of a loss of control after a bio similar to a switch into a bio similar, which in Natalie's case uh did come up.
- 54:24SPEAKER_04: All right, so we're gonna ask you the same question.
- 54:26SPEAKER_04: You may have the same answers before, you may have changed your minds.
- 54:30SPEAKER_04: What would you do in Natalie's case?
- 54:50SPEAKER_04: So it looks like, actually, did it really 100%?
- 54:55SPEAKER_04: It looks like everybody switched aisle 23.
- 54:57SPEAKER_04: Uh any final comments?
- 54:59SPEAKER_08: If I can make a comment, I I really appreciated everyone's reasoning behind why they would or would not uh make a treatment selection of one or the other.
- 55:09SPEAKER_08: The one that impressed me the most was, I believe it was one of our community gastro, the rural gastro community individual who said that they didn't want to be the first in the zip code to prescribe something.
- 55:20SPEAKER_08: I'm really concerned about that, particularly practicing in a tertiary IBD center, and we're always emphasizing the importance of finding the right patient with the right treatment at the right time.
- 55:33SPEAKER_08: And time is of an essence.
- 55:35SPEAKER_08: And so oftentimes these patients are in different parts of the country, rural America, wherever it might be, the suburban, whatever it might be.
- 55:42SPEAKER_08: And then to see or hear that kind of reasoning that that makes me a little concerned.
- 55:47SPEAKER_08: So that was the one comment from all the reasoning that I just really wanted us to pause on a little bit and say, is that really, as healthcare professionals, how we should be practicing?
- 56:00SPEAKER_04: Well, one thing that will come out in the second case, not to give it away too much, is we see that stark contrast as well, where newer therapy, IELT 23 in this case, raises a pause and concern over safety.
- 56:14SPEAKER_04: I think, Anita, to your point, now with you know ACG guidelines, AGA guidelines, um, now long-term extension data with safety, uh, I think the message that I want to make sure we get across, and I think Anita, you're echoing that, is that this is really one of the safest classes of medicines we have in an aisle 23, and we shouldn't limit its use, even though it's newer.
- 56:38SPEAKER_04: And I understand uh that concept, but we do have enough data, especially also with psoriasis and some of the uh rheumatologic indications uh over time.
- 56:49SPEAKER_04: All right, so let's move to the next case.
- 56:51SPEAKER_04: So this is our next uh patient advocate, uh 34-year-old.
- 56:55SPEAKER_04: Now, this is with ulcerative colitis.
- 56:58SPEAKER_04: She's had symptoms for the last three to four months, and you can read through those there.
- 57:02SPEAKER_04: This is impacting her quality of life.
- 57:05SPEAKER_04: She's been on multiple courses of prednisone, and she's worried about long-term effects.
- 57:10SPEAKER_04: And I'm glad to hear that, at least in the first case, the concern about butesinide is a bridge to chronic steroids.
- 57:16SPEAKER_04: Certainly she's worried about this as well.
- 57:19SPEAKER_04: She's been on a 5ASA, both oral and rectal, and she's been on infliximab in the past, and she is feeling discouraged that she's not getting better.
- 57:29SPEAKER_04: Very key important point, bottom right of the slide, is that she is really wanting to start family planning and start trying to get pregnant within the next year.
- 57:39SPEAKER_04: This is a very strong interest that she has, and she did bring that out in her visit.
- 57:44SPEAKER_04: So the endoscopy shows that she does have ulcerative colitis.
- 57:49SPEAKER_04: The mayo endoscopy score is two, so she has moderate colitis.
- 57:53SPEAKER_04: She's not toxic, she doesn't need to be admitted.
- 57:55SPEAKER_04: CRP is high, fecal calpero is high.
- 57:58SPEAKER_04: You can see she's a bit anemic and uh albumin of 3.5.
- 58:02SPEAKER_04: So for all of you, uh, she's been on infliximab, multiple steroids.
- 58:07SPEAKER_04: What would you do next?
- 58:26SPEAKER_04: Again, I want to state, I don't we don't want to sit up here and say there's one absolutely 100% correct answer.
- 58:32SPEAKER_04: I think there's some that are probably more correct than others.
- 58:35SPEAKER_04: Most would use an IELT 23, but some said you patacinitib, some said veto lisumab.
- 58:41SPEAKER_04: Um, maybe Angelina, you know, she said she's interested in getting pregnant in the near term.
- 58:47SPEAKER_04: Is epatocinonib contraindicated in any woman who's interested in getting pregnant, or what's the implications of eupatocinonib in pregnancy?
- 58:56SPEAKER_09: I'm glad you asked it in that way because I don't think every woman, just because they're within an age that they could get pregnant, means that you have to throw out the entire JAC class, right?
- 59:05SPEAKER_09: I just think that when the situation is warranted, when it's the right to Anita's point, actually, you said it really well, right patient at the right time in the right scenario, you pick the medication that's going to be most effective for the patient.
- 59:18SPEAKER_09: In this situation, however, you know, um, or in general, I usually don't necessarily want someone who is actively going, who's thinking about pregnancy like imminently or actively trying to be pregnant.
- 59:30SPEAKER_09: It's not my preference to have someone on UBA.
- 59:33SPEAKER_09: That's in my practice.
- 59:35SPEAKER_09: There are certain scenarios, I know there's been a lot of talk about this in like certain scenarios, patients that are really that have no other options and what you're gonna do.
- 59:44SPEAKER_09: That's not what we're talking about here because she really has only previously been on infliximab and she stopped that because of intolerance, right?
- 59:51SPEAKER_09: I'm curious about those infusion reactions, but that's another topic for another day.
- 59:55SPEAKER_09: So she has a lot of good options for that are that are you know safe in pregnancy.
- 59:59SPEAKER_09: All the biologic agents have really been found to be safe in pregnancy.
- 1:00:02SPEAKER_09: There's a lot of data surrounding um safety in pregnancy and with breastfeeding as well.
- 1:00:08SPEAKER_09: And remember, we really want our patients to breastfeed, right?
- 1:00:12SPEAKER_09: We know that there may be a reduced risk of um of heritability of IBD in uh a baby born to a mom who has um ulcerative clytos or Crohn's disease if you breastfeed.
- 1:00:24SPEAKER_09: So like there's another rationale for just like carrying the medication through not just pregnancy, but also in the postpartum period as well.
- 1:00:30SPEAKER_09: So for me, I would I would prefer to use another agent than UPA in someone who is thinking about pregnancy in the short long term.
- 1:00:41SPEAKER_09: But the only caveat, too, I know this is a long answer, but making sure she's in remission before she tries to conceive is also a super important aspect.
- 1:00:49SPEAKER_09: So it is really important to understand our patient's goals.
- 1:00:51SPEAKER_09: I think this is critically important for us as their provider to understand what their goals are.
- 1:00:56SPEAKER_09: Um, and getting to a healthy pregnancy is good, but we want them to conceive when they're in remission.
- 1:01:01SPEAKER_09: And I would usually love for people to be in remission for six months if we could, um, three months if you are, you know, negotiating, or if times of essence.
- 1:01:10SPEAKER_09: But that's usually what I would want to do.
- 1:01:12SPEAKER_04: Yeah, so I I think the the message is that you patacinitab is not contraindicated in a woman who wants to get pregnant in the future.
- 1:01:19SPEAKER_04: But as Angelina said, if she says, look, this is something I want to try to get pregnant in the next six months to a year, if you did start upato syndicate, you would have to then stop it for a month prior to conception, how long it takes her to conceive a pregnancy then and then switch to something else.
- 1:01:36SPEAKER_04: So I think that's a that's an impact.
- 1:01:38SPEAKER_04: Ed, just briefly on um vitalisumab, what's your thought about betalisumab after infliximab and ulcerative colitis?
- 1:01:45SPEAKER_01: Well, I think that you know the the downside of using vitalismab after a patient's been on an anti-TNF and ulcerative colitis compared to vitalismab first line, is you do see that drop off in the efficacy.
- 1:01:57SPEAKER_01: And I think in somebody that's presenting like her, she's not, as you said, she's not about to be hospitalized, but she certainly is ill.
- 1:02:03SPEAKER_01: And I think given the scenario where we have other therapy choices, just like Angelina said, I think it probably wouldn't be my first choice.
- 1:02:10SPEAKER_01: And I think just to echo one other point about the pregnancy, because her goal is to get pregnant within the next year, you want something that's gonna give her the best chance of getting into remission.
- 1:02:19SPEAKER_01: And so even if my choice was upatocytenin versus veto lismab or epatocytenin versus any of these other things, I would choose upatocytenin to get her into remission and then give her another therapy rather than choose one that I thought might be less effective, at least based on the evidence that we have.
- 1:02:33SPEAKER_04: Yeah.
- 1:02:34SPEAKER_04: So even with that though, let's hear um let's hear the audio for community gastrologists who said switch to veto.
- 1:02:42SPEAKER_02: The patient has at least moderate ulcerative colitis with several flares that have required repeated steroid rescues.
- 1:02:50SPEAKER_02: She's had intolerance to an anti-TNF agent, so best to avoid others.
- 1:02:56SPEAKER_02: Using further steroid therapy is ultimately ineffective and dangerous long term.
- 1:03:02SPEAKER_02: An IL-23 would be acceptable.
- 1:03:05SPEAKER_02: Upatocytinib is very effective, but her prospect of pregnancy makes me inclined to use a relatively gut-specific therapy.
- 1:03:14SPEAKER_02: I would choose vitalismab in this case.
- 1:03:27SPEAKER_02: I would switch to vitalismab.
- 1:03:30SPEAKER_02: She's failed optimize 5 ASA, both orally and rectally, so she needs escalation.
- 1:03:36SPEAKER_02: But she's had prior infliximab intolerance, and she's considering pregnancy within the next year.
- 1:03:44SPEAKER_02: Admittedly, I'm not familiar with evidence for IL-23s in pregnancy.
- 1:03:51SPEAKER_02: I would not continue the 5ASA and reassess later because she's already had an inadequate response to optimized therapy, and waiting prolongs symptoms and increases steroid exposure risk.
- 1:04:06SPEAKER_02: I would not restart the infliximab.
- 1:04:09SPEAKER_02: Not happening.
- 1:04:10SPEAKER_02: She had infusion reactions and systemic intolerance.
- 1:04:16SPEAKER_02: Switching to another anti-TNF agent is the main alternative I'd consider, especially since anti-TNFs have strong pregnancy data.
- 1:04:25SPEAKER_02: But given her prior infusion reaction experience and discouragement, I'm less confident she'll tolerate or stick with another anti-TNF.
- 1:04:36SPEAKER_02: I like IL-23s a lot, but with pregnancy planning within a year, I'm going to choose the option I feel most comfortable with in that scenario and need to know the data with IL-23s in pregnancy.
- 1:04:50SPEAKER_02: I would not switch to upatocytinib when pregnancy is on the table.
- 1:04:54SPEAKER_02: I am not choosing that risk profile here.
- 1:04:58SPEAKER_04: Look at the final bullet points on the left-hand column.
- 1:05:01SPEAKER_04: And this is something I think Aniti kind of brought out before kind of this limited familiarity with IL-23 data in pregnancy.
- 1:05:10SPEAKER_04: And that was really, I think, the driving reason this person said they wouldn't use IL-23.
- 1:05:15SPEAKER_04: They would favor uh Vitlysiumab.
- 1:05:18SPEAKER_04: There's a rural gastroenterologist who picked uh Vitalysiumab and also had the question about safety of other therapies.
- 1:05:29SPEAKER_04: Um and I think this is something that it's interesting to me, you're seeing in a fair balanced way in the real world.
- 1:05:36SPEAKER_04: And I think about a third of you had said Vitaliziumab was an option.
- 1:05:44SPEAKER_02: I would start her on Vetalismab and get her off steroids, ASAP.
- 1:05:48SPEAKER_02: This is moderate to severe ulcerative colitis at this point.
- 1:05:53SPEAKER_02: Three to four months of symptoms, blood, urgency, and incontinence, fatigue, and it's affecting.
- 1:06:00SPEAKER_02: Her ability to work.
- 1:06:02SPEAKER_02: The big red flag is that she's steroid dependent with three plus prednisone tapers in the last year.
- 1:06:09SPEAKER_02: Prednisone is doing the job short term, but it's also quietly wrecking her long-term health.
- 1:06:15SPEAKER_02: I need a durable maintenance therapy that's effective and safe, and I need something I can realistically manage in a rural practice.
- 1:06:24SPEAKER_02: But Elizabet is a strong option because it has a solid long-term safety profile.
- 1:06:30SPEAKER_02: It's effective in ulcerative colitis.
- 1:06:32SPEAKER_02: It helps me stop the steroid cycle.
- 1:06:35SPEAKER_02: And it's a therapy I'm comfortable using and can follow without excessive monitoring complexities.
- 1:06:43SPEAKER_02: Continuing current therapy and attempting another prednisome taper is the definition of steroid dependence.
- 1:06:49SPEAKER_02: Another taper just kicks the can down the road and raises the risk of long-term steroid toxicity.
- 1:06:57SPEAKER_02: Switching to another anti-TNF agent is possible, but not my first move unless she has a clear reason to stay in class.
- 1:07:05SPEAKER_02: Anti-TNFs can work, but if she's already on advanced therapy and still steroid dependent, I'm thinking we need a different mechanism.
- 1:07:15SPEAKER_02: Switching to an IL-23 inhibitor is a good option, but I'm cautious about jumping to newer therapies first line in my practice unless I need to.
- 1:07:24SPEAKER_02: I want more real-world experience, long-term safety data, and payer predictability.
- 1:07:31SPEAKER_02: Switching to upatocytinib is effective and fast, but it comes with more safety concerns and monitoring.
- 1:07:38SPEAKER_02: In my high volume practice, I reserve JAC inhibitors for patients who really need that level of firepower or who fail safer options.
- 1:07:48SPEAKER_02: I don't want to start with the drug that makes me sweat a little.
- 1:07:53SPEAKER_02: Beginning thiopurine monotherapy and reassessing in three to six months would be too slow, not reliably effective enough for this severity, and it doesn't match the urgency here.
- 1:08:06SPEAKER_02: She's already losing function and relying on steroids.
- 1:08:11SPEAKER_04: And then some additional commentary that we got from uh others are switched aisle 23, two said veto.
- 1:08:20SPEAKER_04: Um, but let's get to what did Millie say?
- 1:08:24SPEAKER_05: For case two, Kayla, she has underlying ulcerative colitis.
- 1:08:29SPEAKER_05: My option for what I would do in terms of her management uh would actually be option C, although with a caveat that we also need to consider option D.
- 1:08:40SPEAKER_05: So, you know, when you think about Kayla, she's quite symptomatic with um stools that are frequent with blood and urgency.
- 1:08:47SPEAKER_05: And she's actually required a good number of prednisone tapers over the last uh year.
- 1:08:52SPEAKER_05: And one teaching point, someone should never have recurrent prednisone tapers without a change in therapy.
- 1:08:57SPEAKER_05: When you're initiating steroids, you need to think about what your exit strategy is going to be in terms of maintenance, whether that is a biologic, a small molecule, some form of an advanced therapy.
- 1:09:07SPEAKER_05: Um, so importantly for Kayla, she had previously received inflixema but had intolerance to them.
- 1:09:13SPEAKER_05: Um, not very specific intolerance, but more headache, infusion possible reaction.
- 1:09:19SPEAKER_05: But I always would want to dig in deeper to that because it's a little bit different if the patient just didn't feel quite well as compared to actually having an anaphylactic episode where they had shortness of breath, you know, severe rash, blood pressure drop, et cetera.
- 1:09:32SPEAKER_05: So you want to dig into that and learn more information.
- 1:09:35SPEAKER_05: And importantly, she also had an objective evaluation of her symptoms, meaning she had a fecal calipertectin that was elevated and she had an endoscopy, uh, flexible sigmoidoscopy that showed MAO2 disease, moderate disease.
- 1:09:50SPEAKER_05: And so in this setting, we really need to initiate her on an advanced therapy.
- 1:09:55SPEAKER_05: She previously had that infliction of exposure, which is why it opens up options in another class.
- 1:10:01SPEAKER_05: And so an L23 is reasonable here, um, particularly if she's 34 and is potentially interested in planning a family.
- 1:10:11SPEAKER_05: When we think about planning a family, all of our biologic agents are safe, but we do want to try to avoid an advanced therapy like a jack inhibitor if possible.
- 1:10:22SPEAKER_03: And then how about Jessica?
- 1:10:24SPEAKER_07: For case number two, we have a young woman who has moderate disease, clearly failing 5ASA therapy, has had a previous experience with an anti-TMS that did not go well, and very clearly needs to be in an advanced therapy.
- 1:10:40SPEAKER_07: I think when I'm thinking about this patient, the things I'm taking into consideration are speed, the safety profile.
- 1:10:46SPEAKER_07: And additionally, this patient wants to start a family soon.
- 1:10:50SPEAKER_07: So certainly that's going to play a role when we're considering what therapy to start.
- 1:10:55SPEAKER_07: We know that the Jack inhibitors are currently contraindicated in pregnancy.
- 1:10:59SPEAKER_07: And if this is a patient who's wanting to start, trying to conceive soon, um, I would not use upadacyinym.
- 1:11:07SPEAKER_07: Um, and we know that from the piano registry with Umamaha David.
- 1:11:10SPEAKER_07: So for me, I would choose C, switch to an IL23 inhibitor in this patient.
- 1:11:14SPEAKER_07: Um we know that's going to be safe.
- 1:11:16SPEAKER_07: Um, once we get her into remission, she can safely uh start trying to conceive, um, and she's gonna have some real durability with this agent.
- 1:11:25SPEAKER_04: All right.
- 1:11:26SPEAKER_04: We also show we have some data from the piano study, and I'll show actually the next slides a great table.
- 1:11:33SPEAKER_04: I'm gonna call an audible and just ask for a raise of hands.
- 1:11:36SPEAKER_04: I promise I will not pick on anybody if you raise your hand.
- 1:11:39SPEAKER_04: How many out there do have questions or concerns about aisle 23 in pregnancy?
- 1:11:45SPEAKER_04: I'm I'm curious, and and don't be shy.
- 1:11:48SPEAKER_04: So I do see a few hands out there.
- 1:11:51SPEAKER_04: This is this is something that helps us from an educational standpoint, because I think uh we get used to seeing patients in a tertiary center, and you heard from Anita initially, we don't have concerns about aisle 23 in pregnancy, but that clearly was a theme that came up with a couple of the other comments in the community and rural gastroenterologists.
- 1:12:11SPEAKER_04: The piano registry, um, I think you you've we've kind of outlined this already.
- 1:12:16SPEAKER_04: This is the table that I'll leave up for a second.
- 1:12:19SPEAKER_04: This is uh hot off the press, very recent clinical gastroen app, uh the IVD medications from preconception through pregnancy and lactation.
- 1:12:30SPEAKER_04: And you can see preconception on the left all the way to lactation with the different trimesters.
- 1:12:36SPEAKER_04: And I think the bottom line take home, and I think everybody, if I asked, is methotrexate contraindicating pregnancy would say yes and raise their hand.
- 1:12:44SPEAKER_04: I think we all know that.
- 1:12:46SPEAKER_04: At the very bottom of the slide, the oral small molecules, JAC inhibitors, we haven't talked about the S1Ps, but the S1Ps, azonomod, atrazomod, are also not used in pregnancy.
- 1:12:59SPEAKER_04: But all of the other therapies, the monoclonal antibodies, even thiopurine, amino salicylates, but all the monoclinal antibodies are safe.
- 1:13:09SPEAKER_04: We don't stop them in preconception, we don't stop them in any trimester pregnancy, we don't try to hold the last dose at the end of pregnancy.
- 1:13:18SPEAKER_04: So I think for Kali, and this was educational for me, this concern or question about IL-23 because it's relatively new and the feeling is we have data, this is actually published.
- 1:13:29SPEAKER_04: And I think this table is a guide, uh, is very, very helpful.
- 1:13:34SPEAKER_04: Let's finally hear from uh Ed Loftus.
- 1:13:38SPEAKER_00: So for case two, uh, this is somebody um with active UC.
- 1:13:44SPEAKER_00: They're requiring frequent steroid tapers, they've already failed in fliximab, they didn't tolerate it very well.
- 1:13:50SPEAKER_00: Um importantly, they're interested in uh starting a family in the near future.
- 1:13:56SPEAKER_00: They have objective evidence of inflammation, the CRP, the fecal cow prose up, the uh mayo endoscopic score is two, so there's moderate disease.
- 1:14:06SPEAKER_00: And um, so I think you're definitely want to get them on in advanced therapy.
- 1:14:13SPEAKER_00: Um, you have a lot of different options because they failed in anti-TNF.
- 1:14:17SPEAKER_00: Maybe I wouldn't be, you know, they didn't tolerate it.
- 1:14:20SPEAKER_00: I wouldn't be too interested in that.
- 1:14:21SPEAKER_00: I would probably be thinking of an IL-23 inhibitor, uh UPATACIDNIP.
- 1:14:28SPEAKER_00: Although the fact that she's starting a family soon, I probably would not do UPADACIDNIP.
- 1:14:33SPEAKER_00: If she was saying, yeah, that's something theoretical years away, that would be different.
- 1:14:38SPEAKER_00: Um, so overall, I'd be leaning towards an anti-interleukin.
- 1:14:41SPEAKER_00: I guess veto is an option, although in an anti-TNF failure patient, I'm a little less excited about that as an option, but it would still be a potential option.
- 1:14:52SPEAKER_00: So those would be the two that I'd be talking to the patients about with a slight lean towards the anti-interleukin.
- 1:15:00SPEAKER_09: It might be worthwhile to talk about a failure versus an intolerance, because I think this is a real, this is something that I keep hearing, and I'd say Yeah, so the I I think you can look at it two ways.
- 1:15:11SPEAKER_04: So what Angelina is referring to is we've had patients who've had an intolerance to inflict mab, adolebium ab, and it's kind of vague symptoms, headache, maybe a little bit of fatigue after the injection or the infusion.
- 1:15:26SPEAKER_04: It's not a reaction because of an antibody development to the therapy.
- 1:15:30SPEAKER_04: So I think that's a point well taken.
- 1:15:32SPEAKER_04: We need to kind of keep that in mind.
- 1:15:34SPEAKER_04: And I think about a third of you said veto almost as if that would have been the first-line therapy.
- 1:15:40SPEAKER_04: Even though we're saying that, to be fair, um patient who's been on infliximab says they have an intolerance.
- 1:15:47SPEAKER_04: And in the third case, we'll get to bionaive veto as some data on that that's relatively new, and maybe still using in that bionaive category.
- 1:15:58SPEAKER_04: But I think again, Angelina, um, and actually even ChatGBT agrees with you here.
- 1:16:03SPEAKER_04: They're saying they're saying betaliziumab is reasonable, but maybe go ahead and comment.
- 1:16:08SPEAKER_04: What did you want to say?
- 1:16:09SPEAKER_09: I I just think it's important here always, like I we talked about this in the APP um uh track yesterday, thinking about documentation of medications.
- 1:16:17SPEAKER_09: It's really important to understand when you start a medication, you know, what were the symptoms when you started, and when you stop a medication, why?
- 1:16:23SPEAKER_09: The difference between a primary non-responder, they never got better, versus a secondary loss of response, they initially got better but then couldn't sustain it, flared, versus an intolerance, which is I didn't feel well, something happened, it wasn't anaphylaxis or an allergy, it's just an intolerance.
- 1:16:44SPEAKER_09: Intolerance doesn't mean it was a mechanistic class act failure, it just means that it was an intolerance, and we don't quite understand why typically, right?
- 1:16:52SPEAKER_09: We don't understand if it was really, was it an active part of the drug, was it an inactive part of the drug, is it something else that actually was going on that just it was a confounder?
- 1:17:01SPEAKER_09: So to me, that is very, very, very important.
- 1:17:04SPEAKER_09: And it's the difference between thinking a lot of us would inherently think after an anti-TNF failure, we can't really go to veto, it might not work as well.
- 1:17:12SPEAKER_09: That's what the data tells us, right?
- 1:17:13SPEAKER_09: However, that's not necessarily how this got sorted out, and I just I really just wanted to take a moment about this as a talking point to think through.
- 1:17:22SPEAKER_04: So would you be okay with veto?
- 1:17:24SPEAKER_04: Would I?
- 1:17:24SPEAKER_09: Yes, I would be okay with veto.
- 1:17:26SPEAKER_04: Um Ed, or I'm sorry, Anita and Ed, I want to ask you this specific question.
- 1:17:30SPEAKER_04: So ChatGPT agrees with you.
- 1:17:32SPEAKER_04: So that's uh I don't know if that's good or bad one.
- 1:17:34SPEAKER_03: Chat G agrees.
- 1:17:36SPEAKER_04: Um I want to focus again on the bottom left and the very bottom right.
- 1:17:41SPEAKER_04: So ChatGPT, when we put this through, was focused on the safety and the experience with Vitalysiumab, and even to what we heard from some of the others in the community, raised this question about aisle 23 and are there enough data in pregnancy?
- 1:17:58SPEAKER_04: And when I asked for a show of hands, there were some of you out there were still wondering that.
- 1:18:03SPEAKER_04: Anita, can we put this to rest?
- 1:18:05SPEAKER_04: Is is are you comfortable with aisle 23 in pregnancy?
- 1:18:08SPEAKER_08: Yes.
- 1:18:10SPEAKER_04: Very good.
- 1:18:12SPEAKER_04: A woman of few words.
- 1:18:13SPEAKER_01: Ed?
- 1:18:14SPEAKER_01: Yeah, maybe I'll use a few more words.
- 1:18:16SPEAKER_01: I would say I would say yes.
- 1:18:18SPEAKER_01: And the the graph that you are the sorry, the table that you showed, just so everybody knows where that came from.
- 1:18:23SPEAKER_01: That's from the Global Consensus Guidelines on the Management of Pregnancy.
- 1:18:26SPEAKER_01: And I I was lucky enough to be involved in that.
- 1:18:29SPEAKER_01: And what we did is I was one of the grade methodologists.
- 1:18:31SPEAKER_01: So we looked at all the available evidence for all of these questions that you got that we're asking about how to manage pregnant patients with IBD.
- 1:18:39SPEAKER_01: And so, you know, I'm biased because I was involved in it, but the point of telling you this is it it really is a helpful document because it goes through every single question you could potentially have, in my opinion, about how to manage a pregnant patient with IBD or a patient who's contemplating pregnancy with IBD, and what is the evidence that would support how you would manage that patient during the course of that pregnancy.
- 1:19:02SPEAKER_01: And if we don't have evidence for that, I think one of the really novel things that we did in this global consensus guidelines is because all of the experts that were involved in the room were from all over the world, we had these key concept statements that Uma and Millie and people came up with to say, how should we manage it in the absence of evidence?
- 1:19:20SPEAKER_01: And so it's very clinically focused.
- 1:19:22SPEAKER_01: And so if you haven't seen that document, I would definitely encourage you to say that.
- 1:19:25SPEAKER_01: So that is a little bit longer answer than yes, but I do feel comfortable with the But yes is your answer.
- 1:19:30SPEAKER_04: Yes, is it?
- 1:19:31SPEAKER_04: Comfortable with IL23.
- 1:19:32SPEAKER_04: Uh the um again, the data from this and the table, which is in the publication, will be shared with you after this conference.
- 1:19:40SPEAKER_04: So all of this is something that you'll have.
- 1:19:43SPEAKER_04: Let's listen to Kayla.
- 1:19:45SPEAKER_06: My name is Kayla White.
- 1:19:47SPEAKER_06: I am an inflammatory bowel disease patient, student, and IBD advocate.
- 1:19:52SPEAKER_06: Um, I was initially diagnosed in May of 2020.
- 1:19:56SPEAKER_06: The pandemic definitely made my diagnosis a little bit harder due to hospitals being chaos.
- 1:20:03SPEAKER_06: Specialists stopped refusing to take new patients.
- 1:20:06SPEAKER_06: And overall, being in that transition period between being a peas patient and an adult patient, I was 17 years old.
- 1:20:14SPEAKER_06: Um, I want to say at first I started noticing blood in my stool and frequency um when I had to use the bathroom immediately after eating.
- 1:20:22SPEAKER_06: From that, things kind of progressed just to more pain, joint swelling, skin irritations, fatigue.
- 1:20:29SPEAKER_06: And I was a pretty textbook IVD patient, which definitely made my diagnosis a lot easier.
- 1:20:36SPEAKER_06: I was diagnosed via colonoscopy and biopsies.
- 1:20:40SPEAKER_03: And then I think we have a little bit more.
- 1:20:44SPEAKER_06: I went to New York and then immediately things just started getting worse from there.
- 1:20:49SPEAKER_06: Um, I was always so stubborn and really academically driven.
- 1:20:53SPEAKER_06: So my mom was like, Kayla, you should come home.
- 1:20:55SPEAKER_06: But I'm just like, give another week the minutes to start working, or I'll have a virtual appointment with my doctor so they can kind of see what's going on.
- 1:21:03SPEAKER_06: I came home because I was missing class and it just wasn't sustainable anymore for me to be away from my family.
- 1:21:09SPEAKER_06: And once I got off the plane, got home, slept because I got in that night and then went to hospital, went to the hospital the next morning.
- 1:21:18SPEAKER_06: They checked my level of my inflammation was off the charts.
- 1:21:22SPEAKER_06: And my doctors told me that if I would have stayed in my dorm another day longer, I probably would have passed out.
- 1:21:28SPEAKER_06: And due to me having a single dorm for um academic accommodations, I don't think my friends would have noticed until a day or two that I wasn't coming um to class anymore.
- 1:21:38SPEAKER_06: So that kind of is what got me to a stopping point in 2021 where I was faced with do I want to continue with medications or do I want to try and get surgery.
- 1:21:53SPEAKER_04: So again, I want to thank Kayla, as I did Natalie, for really participating in this program.
- 1:21:59SPEAKER_04: There's a lot of vulnerability, but you also hear the resilience in our patients, which to me is incredibly inspiring.
- 1:22:05SPEAKER_04: And I see this in my clinics and hear what these patients are going through.
- 1:22:09SPEAKER_04: So thank you for our patient advocates.
- 1:22:12SPEAKER_04: In terms of case two, this is just a summary, and you do see a bit of a split.
- 1:22:16SPEAKER_04: Um, so five said aisle 23.
- 1:22:19SPEAKER_04: Um, I think on the panel, I would be in the aisle 23, so three of us said aisle 23, but Angelina, I think uh veto because it wasn't necessarily a failure of inflixamath, and I think we're hearing that as well.
- 1:22:32SPEAKER_04: And I think some of the take-homes for this is all of us agree that steroids are not a long-term option, and that does mean that we should move to another therapy.
- 1:22:42SPEAKER_04: Um, and then this question about treatment and tolerance versus failure, and then therapy selection.
- 1:22:48SPEAKER_04: So let's ask all of you, then we'll we'll end with the third case, and then I am definitely going to leave time because there are a lot of questions that are great, so I'm gonna make sure we have time at the end.
- 1:22:57SPEAKER_04: But what would you do?
- 1:22:58SPEAKER_04: Any changes in how you would uh treat uh Kayla?
- 1:23:20SPEAKER_04: It sounds like most of you actually now are favoring an IL-23 uh veto.
- 1:23:25SPEAKER_04: Um when I talk about thiopurine, I'll tell you that thiopurines exclusively for me are used in combination with infliximab.
- 1:23:32SPEAKER_04: So I think that probably now would be considered a wrong action, wrong answer.
- 1:23:37SPEAKER_04: Yupah's okay, but if she's really trying to get pregnant or getting pregnant soon, I think that's something we consider.
- 1:23:43SPEAKER_04: And then you heard the rest.
- 1:23:45SPEAKER_04: All right, so let's end with the final case, and this also gives some interesting discussion points that you may see in your practices.
- 1:23:52SPEAKER_04: A 28-year-old.
- 1:23:54SPEAKER_04: Now, this is a brand new diagnosis of Crohn's disease, having symptoms, it's affecting his quality of life, he's lost some weight, he's been on butesinide, that's really been the primary treatment, and he's also worried about long-term steroids.
- 1:24:09SPEAKER_04: He has never been on any other therapy, so this is a brand new diagnosis of Crohn's disease.
- 1:24:15SPEAKER_04: He has inflammation in the ilium and then the cecum, and as you heard Millie Long say, an SCSCD of 12 means that this is certainly moderate to severely active, doesn't have any complications, but you can see from his inflammatory markers they're elevated.
- 1:24:30SPEAKER_04: Also, his fecal cow protectin' is pretty high and didn't get that much better with butestinide.
- 1:24:35SPEAKER_04: He is anemic and his albumin's right at the end of normal.
- 1:24:40SPEAKER_04: So what would you do for him?
- 1:25:01SPEAKER_04: Not to make a generalization, we may see this case less than you, meaning that sometimes when a patient's referred to a tertiary center, they've already been seen up treated, and now they're coming in.
- 1:25:15SPEAKER_04: So this is great.
- 1:25:16SPEAKER_04: Actually, this is really good because nobody's putting one, I mean, even though TNF probably by percentage uh was a little bit higher than an IL23, even UPA, veto, um 5S8, by the way, I was maybe you actually had somebody vote because you said that.
- 1:25:34SPEAKER_04: 5SA is a wrong answer.
- 1:25:36SPEAKER_04: I that this is one time I can say uh that it is a wrong answer.
- 1:25:40SPEAKER_04: The data with misalamine in Crohn's disease, especially ilioclinic Crohn's, um, is not there's no efficacy at all.
- 1:25:49SPEAKER_04: So I would not use a 5SA in this uh class.
- 1:25:53SPEAKER_08: Um I will add, we Yeah, I was gonna ask your your thoughts.
- 1:25:57SPEAKER_04: So let's go down the panel.
- 1:25:58SPEAKER_04: Yeah, go ahead.
- 1:25:59SPEAKER_08: Even in our updated Crohn's disease guidelines, we were very intentional with bringing home and taking home that message for us, not just for us as prescribers, but even for our payers to recognize, because certainly there are still some insurance companies that are still mandating a 5ASA in Crohn's disease.
- 1:26:17SPEAKER_08: So we've incorporated that in our Crohn's disease guidelines, the living guidelines through the ACG.
- 1:26:22SPEAKER_04: All right.
- 1:26:22SPEAKER_04: So I'm gonna go down to each of you.
- 1:26:24SPEAKER_04: And Anita, I'll start with you.
- 1:26:25SPEAKER_04: Uh if we come back to the audience response, or we can just do this.
- 1:26:29SPEAKER_04: Anita, which would you which therapy for just say the name of the therapy?
- 1:26:33SPEAKER_08: Oh the name of the therapy?
- 1:26:35SPEAKER_04: Yep.
- 1:26:36SPEAKER_08: Um I would do I would do gasilcumab.
- 1:26:40SPEAKER_04: Okay, gasel cumab.
- 1:26:41SPEAKER_04: Angelina?
- 1:26:42SPEAKER_09: I would do gasalcumab sub Q induction.
- 1:26:44SPEAKER_04: Ed?
- 1:26:45SPEAKER_01: I would do influximab azothibrin combo.
- 1:26:48SPEAKER_04: Okay.
- 1:26:49SPEAKER_04: So you're hearing kind of some differences, and I think the audience, it was a little bit higher TNF inhibitor than an IL-23.
- 1:26:57SPEAKER_04: Um, and again, um actually let me ask um Anita, you pad a synonym, uh, what about that for first line therapy?
- 1:27:05SPEAKER_04: The label change, does that help you say that's okay to use?
- 1:27:10SPEAKER_08: It does help me say it's okay to use in the right patient, but this patient is not knocking on fully on the hospital door.
- 1:27:16SPEAKER_08: I mean, as far as how rapidity of onset and and and all the rest that I would want or need in this situation, I I would still feel very comfortable with having an IL-23 specifically as a class, knowing both rapidity and efficacy is comparable and a safety is a superior.
- 1:27:33SPEAKER_04: Yeah, the one one comment I'll make, and you probably all saw this, I think it was in October the FDH did change the label for UPATIS synonym.
- 1:27:41SPEAKER_04: So patients who've been on not just a TNF but systemic therapy.
- 1:27:45SPEAKER_04: Now it gets a little bit vague.
- 1:27:46SPEAKER_04: What's systemic therapy and who are inappropriate to a TNF?
- 1:27:51SPEAKER_04: What's inappropriate to a TNF?
- 1:27:53SPEAKER_04: So there is a bit of vagueness in the language.
- 1:27:56SPEAKER_04: Now, some people would say systemic therapy would include a steroid.
- 1:28:00SPEAKER_04: Um so a steroid could be considered systemic.
- 1:28:03SPEAKER_04: Um I'll just say that that's a little bit vague, um, but I agree with uh kind of what you said, Anita.
- 1:28:09SPEAKER_04: So let's um uh let's go to the community.
- 1:28:14SPEAKER_02: He should be tried on an advanced therapy at this point, having failed conventional therapy and having at least moderately severe Crohn's.
- 1:28:23SPEAKER_02: I would use an IL-23, avoid further steroid use, and I believe that an IL-23 is most likely to affect clinical and deep remission as opposed to conventional therapy, misalamine or vetalismab.
- 1:28:38SPEAKER_02: Upatocytinib would be a reasonable therapy in this situation, but guidelines suggest not using it as first-line therapy before an advanced systemic therapy is tried.
- 1:28:50SPEAKER_02: I would use it second-line if IL-23s do not deliver results.
- 1:28:57SPEAKER_02: I would initiate an anti-TNF agent.
- 1:29:00SPEAKER_02: This guy has moderate Crohn's, SES CD12, iliocal involvement, persistent symptoms for three months, weight loss, and he failed buticenide.
- 1:29:11SPEAKER_02: He's biologic naive, so I want the therapy with the deepest track record, the most predictable insurance path, and the highest chance of working fast enough to stop the slow decline.
- 1:29:23SPEAKER_02: I'm going with an anti-TNF because it's a known quantity and I've used it forever.
- 1:29:29SPEAKER_02: Also, it is effective for moderate to severe Crohn's, including ileal disease.
- 1:29:34SPEAKER_02: It's a practical first biologic with real-world data and clear troubleshooting.
- 1:29:40SPEAKER_02: If he doesn't respond, I can still pivot to another mechanism later.
- 1:29:45SPEAKER_02: I'm not starting with the newest quote-unquote big guns before I even know how he behaves on therapy.
- 1:29:53SPEAKER_02: I'm trying to avoid the pattern of switch to flare to steroid rescue and more switching.
- 1:29:59SPEAKER_02: I'd rather start strong and optimize.
- 1:30:03SPEAKER_02: I like the safety of initiating Vetalism ab, but in Crohn's, especially ileol, it can be slower and less reliable for what I'm seeing here.
- 1:30:12SPEAKER_02: He's losing weight and still symptomatic after Budecinide.
- 1:30:16SPEAKER_02: I don't have time for maybe.
- 1:30:20SPEAKER_02: I haven't used IL-23s in my practice yet.
- 1:30:23SPEAKER_02: They look great, but I want more hands-on experience and real-world comfort first.
- 1:30:30SPEAKER_02: Also, if I start there and it fails, I've burned a premium option early.
- 1:30:35SPEAKER_02: I don't want my first IL-23 patient to be the one who doesn't read the brochure.
- 1:30:43SPEAKER_02: Initiating Upadacitnib could be effective, but it's not where I start in a biologic naive Crohn's patient when I have other proven options.
- 1:30:54SPEAKER_02: More safety monitoring, more staff work, and more anxiety for me and the patient.
- 1:31:00SPEAKER_02: Initiating 5ASA therapy would not be an effective strategy for ileocecal Crohn's with this severity.
- 1:31:09SPEAKER_02: This isn't a let's try something gentle situation.
- 1:31:15SPEAKER_02: Initiating thalopurine monotherapy and reassessing in three to six months is too slow, not dependable enough, and I'm not letting him decline while he loses more weight and stays inflamed.
- 1:31:28SPEAKER_04: And then another community gastroenterologist said an IL-23.
- 1:31:33SPEAKER_02: I would initiate an IL-23 inhibitor.
- 1:31:36SPEAKER_02: This is a biologic and small molecule naive 28-year-old man with moderate ilioceal Crohn's disease, SES CD12, persistent symptoms for three months, weight loss, and failure of butesenide.
- 1:31:50SPEAKER_02: He's clearly beyond watch and wait.
- 1:31:53SPEAKER_02: For him, I want durable control, strong mucosal healing potential, and a plan he can actually live with long term.
- 1:32:02SPEAKER_02: The IL-23 data are impressive, and the subcutaneous dosing is a huge quality of life win, especially for a young, active patient trying to maintain work, gym, and social life.
- 1:32:16SPEAKER_02: So I'm starting an IL-23 inhibitor because it's high efficacy for Crohn's disease.
- 1:32:21SPEAKER_02: It offers durability, not just quick symptom suppression.
- 1:32:25SPEAKER_02: Sub Q maintenance fits his lifestyle and reduces treatment friction.
- 1:32:30SPEAKER_02: It avoids the quote-unquote anti-TNF baggage some patients run into, like immunogenicity, secondary loss of response, etc.
- 1:32:40SPEAKER_02: And it aligns with modern treat-to-target thinking.
- 1:32:44SPEAKER_02: Control inflammation early, prevent progression.
- 1:32:48SPEAKER_02: I'm not saving the best tool for later while he's actively inflamed now.
- 1:32:57SPEAKER_02: Initiating an anti-TNF agent is totally reasonable and still a great option, but if I'm choosing based on current evidence and patient lifestyle, an IL-23 is where I'm going first for long-term durability and convenience.
- 1:33:15SPEAKER_02: I like the safety profile of Vetalismab, but for ileal crohns and a patient already losing weight after butesenide, I want something with stronger and more predictable efficacy.
- 1:33:28SPEAKER_02: Initiating upatocyt nib could be effective, but I usually reserve jacks for later lines or specific scenarios.
- 1:33:37SPEAKER_02: For a young biologic naive patient, I'd rather start with a therapy with an excellent efficacy profile and a cleaner long-term risk monitoring vibe.
- 1:33:48SPEAKER_02: I would not initiate 5ASA therapy.
- 1:33:52SPEAKER_02: 5ASA isn't appropriate for moderate iliocecal crohns.
- 1:34:00SPEAKER_02: Initiating thiopurine monotherapy and reassessing in three to six months is too slow, not reliable enough, and risks delaying control while disease progresses.
- 1:34:14SPEAKER_04: And then the other respondents kind of split.
- 1:34:18SPEAKER_04: So what did Millie say?
- 1:34:21SPEAKER_05: For case three, Brandon.
- 1:34:23SPEAKER_05: Brandon is quite symptomatic and he has right-sided inflammation.
- 1:34:28SPEAKER_05: My choice for Brandon's management would be D initiate an anti-TNF therapy with a little bit of an asterisk in that I use combination therapy with a thiopurine with an anti-TNF in the first six months to help to prevent immunogenicity.
- 1:34:43SPEAKER_05: So I would check a TPMT and potentially initiate a thiopurine with the TNF.
- 1:34:49SPEAKER_05: And in fact, I would actually use specifically infliximab.
- 1:34:53SPEAKER_05: I do think infliximab um in terms of the anti-TNF agents is my go-to in terms of the highest efficacy.
- 1:35:01SPEAKER_05: So that said, he is naive to other agents.
- 1:35:05SPEAKER_05: And so I think this is someone who you could consider an L-23 inhibitor.
- 1:35:10SPEAKER_05: You certainly could consider vitalismam.
- 1:35:13SPEAKER_05: I don't choose vitalismab as readily in someone with predominantly ileal disease.
- 1:35:18SPEAKER_05: I just don't think it has as great efficacy.
- 1:35:21SPEAKER_05: And a JAC inhibitor is something we could consider.
- 1:35:25SPEAKER_05: Now remember that JAC inhibitors, the initial label said that they should only be used after a TNF agent.
- 1:35:32SPEAKER_05: But the updated label says that it can be used after other systemic therapy if it's inadvisable to use a TNF.
- 1:35:40SPEAKER_05: At this point, I don't think it's quite inadvisable to use a TNF, so I might still reserve that, but remember that label change for future use of upavacytin.
- 1:35:51SPEAKER_05: Now, there is one answer here that is clearly wrong.
- 1:35:54SPEAKER_05: All of our guidelines recommend against initiating mesanolamine, so that should just not be done in iliocecal Crem's disease.
- 1:36:02SPEAKER_05: So that is truly the wrong answer.
- 1:36:04SPEAKER_05: In reality, our data truly show that early initiation of advanced therapy improves outcomes.
- 1:36:10SPEAKER_05: And I think that any of these agents could be utilized.
- 1:36:13SPEAKER_05: I think you could have a shared decision-making discussion with the patient himself over what he could potentially be most effective with and adherent to.
- 1:36:24SPEAKER_05: I do emphasize that he he really has been using butestinide and other things.
- 1:36:29SPEAKER_05: Remember that no one should have recurrent courses of steroids, whether that's budestinide or prednisone.
- 1:36:34SPEAKER_05: We really need to be thinking about an exit strategy.
- 1:36:39SPEAKER_04: Great.
- 1:36:39SPEAKER_04: And so Ed, by the way, is at University of North Carolina.
- 1:36:42SPEAKER_04: Millie Long is the chief of the University of Carolina, and their answer was identical.
- 1:36:47SPEAKER_04: Exactly.
- 1:36:47SPEAKER_04: So inflicts amnesia thyprin.
- 1:36:49SPEAKER_04: I'm just making that point.
- 1:36:51SPEAKER_09: I already made it under my breath.
- 1:36:53SPEAKER_04: I want to have a job on Monday.
- 1:36:55SPEAKER_04: Let's get a Jessica Algredi.
- 1:36:58SPEAKER_04: None of us are with Jessica, so let's see what she said.
- 1:37:02SPEAKER_07: For case number three, we have a young man who's newly diagnosed or recently diagnosed with ilioclinic hearing disease and clearly needs to be advanced to an advanced therapy.
- 1:37:12SPEAKER_07: And so this will be the first advanced therapy that this patient is starting.
- 1:37:17SPEAKER_07: We know that he's got fairly significant disease, fecal cow protectant in the thousands, getting worse after a steroid course.
- 1:37:25SPEAKER_07: And so I think there, again, there are a few potential paths that we could take with this patient.
- 1:37:31SPEAKER_07: That being said, he doesn't have any big red flags for me that would require an anti-TNF initiation out the gate.
- 1:37:39SPEAKER_07: So I probably would withhold that until later in his disease course should he need it.
- 1:37:44SPEAKER_07: And again, this is a patient where I think an IL-23 inhibitor actually would be most appropriate.
- 1:37:50SPEAKER_07: It's a great first line agent, an excellent safety profile.
- 1:37:53SPEAKER_07: We know it's going to be effective and durable and work fast for him.
- 1:37:57SPEAKER_07: This is likely not a patient where I would want to initiate V-delisimab given how sick he appears to be, and also has primary, primarily ilele disease.
- 1:38:08SPEAKER_07: And typically, even though we have label changes with upatocytinive giving us a little bit more broad usage, I still am not typically using that first line.
- 1:38:19SPEAKER_04: All right.
- 1:38:32SPEAKER_00: So case three is a guy with Crohn's who has had recent increased symptoms.
- 1:38:38SPEAKER_00: He's worried about the effects of steroids.
- 1:38:42SPEAKER_00: He's been on butesenide.
- 1:38:44SPEAKER_00: He has definite uh evidence of inflammation, his fecal, CalPro, and CRP are high.
- 1:38:48SPEAKER_00: He's got an SESCE score of 12, which indicates at least moderate activity.
- 1:38:54SPEAKER_00: Um and previously, um, I mean, here things are wide open because they're they're advanced therapy naive.
- 1:39:02SPEAKER_00: Um, of the choices listed, I would be considering either veto, an anti-IL23, or an anti-TNF agent.
- 1:39:13SPEAKER_00: I wouldn't probably pull the trigger on you patocydina this early, and I wouldn't be doing thiopurine monotherapy anymore.
- 1:39:21SPEAKER_00: Uh, I also wouldn't be doing 5ASA since this is Crohn's disease.
- 1:39:25SPEAKER_00: And so um of those options, the two that I would be most in favor of would be either the anti-enterleukin or the anti-TNF.
- 1:39:34SPEAKER_00: Again, probably if veto is going to be used in Crohn's disease, probably the best time to use it is in a patient like this who's advanced therapy naive.
- 1:39:43SPEAKER_00: We know that from the uh Love C D trial that that's when veto works the best in Crohn's, is in a patient like this.
- 1:39:51SPEAKER_00: So there's those are three options.
- 1:39:53SPEAKER_00: I'd be leaning mostly towards the anti-interleukin or the anti-TNF.
- 1:39:58SPEAKER_00: Um, out of habit, probably, I've been doing more anti-TNF, but now we have so many options available.
- 1:40:05SPEAKER_00: Anti-interleukin would be a great option too.
- 1:40:11SPEAKER_04: And another thing, if you did use an anti-interleukin first as a systemic therapy, you are open to use UPATA synonym after that.
- 1:40:19SPEAKER_04: Um, we wanted to show you this.
- 1:40:21SPEAKER_04: This was just published, so many of you may not have seen this study.
- 1:40:25SPEAKER_04: And this gets to how does veto work for first-line Crohn's disease?
- 1:40:29SPEAKER_04: And this Brandon's case is perfect for this.
- 1:40:33SPEAKER_04: One, it's a bio-naive.
- 1:40:35SPEAKER_04: Second, is it's early after diagnosis.
- 1:40:38SPEAKER_04: That is the key important factors.
- 1:40:41SPEAKER_04: And you can see early Crohn's is the dark, the blue is late Crohn's, and you can see a separation that if you were to use veto as the first line therapy early, there are efficacy data in Crohn's.
- 1:40:54SPEAKER_04: So, to be completely fair balanced, if you were to use veto for Crohn's, use it as first line very early.
- 1:41:01SPEAKER_04: That's that would be my take-home.
- 1:41:03SPEAKER_04: You heard before when we talked about infliximab, again, whether it was intolerance or failure, but veto after an advanced therapy, certainly in Crohn's disease, uh, would not be appropriate.
- 1:41:14SPEAKER_04: And I think you can even see in the late group, some of those patients had been on other therapies.
- 1:41:20SPEAKER_04: What did Chat GBT say?
- 1:41:22SPEAKER_04: Uh, it also picked a TNF inhibitor, so I think again the majority still uh picked that.
- 1:41:28SPEAKER_04: And then the case perspective, it's it's really a split here.
- 1:41:33SPEAKER_04: And I guess one question I want to ask the group before we have you all vote again, and then we'll get to some of the questions.
- 1:41:40SPEAKER_04: Um Ed kind of mentioned this, and I think as we all become more familiar with an IL-23, is there a reason in this kind of patient that we would not just say we're using IL-23 first?
- 1:41:54SPEAKER_04: The data look very good.
- 1:41:56SPEAKER_04: There's not a head-to-head yet in the designed way we want with IL-23 compared to a TNF inhibitor like in Fliximab.
- 1:42:04SPEAKER_04: Again, if you really were to be fair balanced, that's the trial you want.
- 1:42:07SPEAKER_04: We don't have that.
- 1:42:09SPEAKER_04: The safety is so good with an IL-23, the efficacy is so good.
- 1:42:13SPEAKER_04: Is there any reason we shouldn't be using IL-23 first line?
- 1:42:17SPEAKER_04: So I'm gonna ask each of you the same question, maybe go down the line.
- 1:42:20SPEAKER_04: Uh Anita first and then Angelina.
- 1:42:22SPEAKER_04: Oh, I wanted to go first this time, but go ahead.
- 1:42:25SPEAKER_09: Okay.
- 1:42:26SPEAKER_09: I still actually look like so excited.
- 1:42:30SPEAKER_09: I don't want to take it away from it.
- 1:42:33SPEAKER_04: We realized with the headset and the little jacket.
- 1:42:35SPEAKER_04: So I know go ahead.
- 1:42:36SPEAKER_09: All right, sportscaster, newscaster.
- 1:42:39SPEAKER_09: Um I think you look chic.
- 1:42:44SPEAKER_04: I have to be very careful what I say.
- 1:42:46SPEAKER_04: So just go ahead and talk about it.
- 1:42:49SPEAKER_04: Exactly.
- 1:42:50SPEAKER_04: Okay, okay.
- 1:42:50SPEAKER_04: We have a lot of people.
- 1:42:51SPEAKER_04: All right.
- 1:42:52SPEAKER_09: I still think in a situation of more severe disease, closer to hospital admission, deep ulcerations, I my I would still I would probably favor uh infliximab azothioprin combination therapy.
- 1:43:04SPEAKER_09: I do, like the UNC folks, I do use combination therapy of anti-TNF and immunomodulator in that situation.
- 1:43:10SPEAKER_09: So if these were deep ulcerations, there's a significant, I know there's some data on stricturing disease and ability for IL-23 and stricturing disease, but even still, I think that I would favor in a sicker-looking patient and uh even more severe disease and ileal disease as well.
- 1:43:28SPEAKER_09: Because ileal disease, we didn't talk about this, but this is that's another beast of uh another phenotypic beast, I think, in treatment.
- 1:43:34SPEAKER_09: I would favor um inflixomabies of thyroid and in a sicker patient.
- 1:43:38SPEAKER_04: A sicker patient, and then uh maybe Anita, and in a patient who maybe doesn't have the ulcers, we didn't talk about perianal disease, doesn't have perianal disease.
- 1:43:48SPEAKER_04: What why would you not pick IL-23 first?
- 1:43:51SPEAKER_04: Or is that your go-to now for a patient with Crohn's iliocolitis?
- 1:43:55SPEAKER_08: Yeah, so it still remains an IL 23 as a go-to for for the naive patient.
- 1:44:01SPEAKER_08: One thing uh I wanted to highlight, and maybe uh the sicker, and that's what I was emphasizing as far as that burden of disease that the patient is suffering from.
- 1:44:09SPEAKER_08: We will here soon have results from fusion, which is the gazilcomab perienal fistalizing disease.
- 1:44:18SPEAKER_08: And so that's going to be really great to see because at present we only have that kind of level of studies with infliximab.
- 1:44:25SPEAKER_08: That's why we always think perianal disease, influximab, right?
- 1:44:29SPEAKER_08: Um so I didn't fully answer your question, but I I would still consider that in this patient, so as long as the factors that Angelina pointed out.
- 1:44:37SPEAKER_04: And then Ed, you still uh would you still use influximab basethyperin?
- 1:44:41SPEAKER_04: Say it's again not deep ulcers, no perianal disease, moderately active Crohn's iliocolitis, is that still your first go-to, or are you starting to use IL-23 more?
- 1:44:50SPEAKER_01: Yes, so I don't think IL-23 is wrong.
- 1:44:52SPEAKER_01: You know, and and earlier we were just given the one-word answer, but so it's it's hard to sort of elaborate.
- 1:44:57SPEAKER_01: But I think in this particular case, and may and so I'm using IL-23 more.
- 1:45:01SPEAKER_01: That's the answer to the to your question.
- 1:45:03SPEAKER_01: The rationale in this particular case is, you know, if I think about this guy that's really only had disease for a short period of time.
- 1:45:10SPEAKER_01: This is not profile where it's 12 days, right?
- 1:45:13SPEAKER_01: But it's probably as close as we're going to see in practice in the United States, and he's already been on butesinine and his fecal cow protectin went up.
- 1:45:19SPEAKER_01: So maybe he's the other arm of profile.
- 1:45:23SPEAKER_01: And those patients still had some of the highest remission rates that we saw in any clinical trial in the step-up arm.
- 1:45:30SPEAKER_01: And so he's sort of the steroid step-up arm.
- 1:45:33SPEAKER_01: They got to like 60% at six months, and the other arm was 80% at 12 months.
- 1:45:38SPEAKER_01: So that's sort of how I rationalize this particular case.
- 1:45:40SPEAKER_04: Yeah, and just to be clear, we didn't um outline the profile study.
- 1:45:44SPEAKER_04: Uh, for anybody who has journal clubs, you should do the profile study.
- 1:45:49SPEAKER_04: It's a European-based study within two weeks, two weeks of diagnosis.
- 1:45:54SPEAKER_04: So not a few months, a couple years, two weeks of diagnosis, top-down with primarily infliximab azothioprin versus step up.
- 1:46:03SPEAKER_04: And to Ed's point, we saw some of the highest remission rates we've seen of any study.
- 1:46:08SPEAKER_04: And what I want to bring up on this slide is, and I'll say this with absolute fair balance and objectivity, I think in newly diagnosed Crohn's, until we have head-to-head data, it may not matter what therapy we use as long as we use it very early and know that we need to monitor and switch.
- 1:46:28SPEAKER_04: The reason I asked the question about IL-23 with the safety profile being so good and now seeing endoscopic improvements and efficacy, and now the fact that I can go to eupatocidib is the second line.
- 1:46:41SPEAKER_04: I am tending to use uh IELT 23 first.
- 1:46:44SPEAKER_04: And just to answer a question I asked the panel before, I am using Gaselcuma primarily because the subcutaneous induction is so easy for me to start and they can stay on it without getting a second payer approval uh at the maintenance dose.
- 1:47:00SPEAKER_04: So just to be clear, it's not a head-to-head efficacy amongst IL23s.
- 1:47:05SPEAKER_04: And if you used another one, that would be perfectly uh acceptable based on efficacy, but because of the subcutaneous induction.
- 1:47:13SPEAKER_04: Anita, you want to make a point, and then as you're making the point, if the audience can respond again in terms of what you would do for Brandon, this new onset Crohn's iliocolitis patient.
- 1:47:48SPEAKER_08: First of all, when I start an anti-TNF, I always, at least for the majority, do combination therapy, right?
- 1:47:55SPEAKER_08: So for that first six to twelve months, I'm doing combination therapy, unless there's contraindications, older patient, et cetera.
- 1:48:02SPEAKER_08: So with that said, in a young patient, new diagnosis, burden of disease, quality of life, everything else, I want to, again, going back to that easy button.
- 1:48:10SPEAKER_08: How do I get him back to feeling normal?
- 1:48:13SPEAKER_08: That's the word that our patients say.
- 1:48:15SPEAKER_08: When do I get to go back to feeling normal?
- 1:48:17SPEAKER_08: So that's another reason why I would not consider it an anti-TNF because I do comma therapy.
- 1:48:23SPEAKER_04: Right.
- 1:48:23SPEAKER_04: So that kind of speed of onset.
- 1:48:26SPEAKER_04: Um, so points very well taken.
- 1:48:29SPEAKER_04: So we do have a few more people saying they would use aisle 23 first line, and then I still think in kind of second place is TNF.
- 1:48:37SPEAKER_04: Yupa kind of dropped off.
- 1:48:39SPEAKER_04: Um I'm happy to say this again with fairness that uh misalamine dropped off.
- 1:48:43SPEAKER_04: I'm happy to see that.
- 1:48:45SPEAKER_04: Uh, and then veto, um, again, there's still some that would say that's okay, but really it's coming down between the aisle 23 and the TNF.
- 1:48:54SPEAKER_04: Um, I'm gonna finish out the slide parts, but now I have a lot of questions that I'm gonna get to.
- 1:48:59SPEAKER_04: Somebody asked me what I would do in Brandon's case, and I think I answered it already, but I'll say it again.
- 1:49:04SPEAKER_04: I would use an aisle 23 because if it were not to work, TNF is still an option, you patocydenib is still an option.
- 1:49:13SPEAKER_04: Because of the ease of subcutaneous induction, I am using Gasel QMab, not because it's better than Risen Kizimab or Miran Kizimab.
- 1:49:20SPEAKER_04: There are no data head-to-head.
- 1:49:22SPEAKER_04: So just to be fair, um, but because of the sub Q.
- 1:49:26SPEAKER_04: So I think we covered some of this uncontrolled disease demands and not delaying uh mechanism matters.
- 1:49:33SPEAKER_04: We are seeing IELT 23 as a class.
- 1:49:36SPEAKER_04: Uh efficacy alone is not enough, so we have to consider the patient, route of administration, safety, uh, and kind of the right therapy for the right patient.
- 1:49:46SPEAKER_04: These are kind of the SMART goals that we covered already, but improving your confidence uh in using these different therapies.
- 1:49:54SPEAKER_04: Uh, shared decision making, which I think obviously you heard from our patients and our cases.
- 1:49:59SPEAKER_04: Uh The IL23 class, which I think we are seeing starting to rise as an earlier and first-line therapy, and then obviously avoiding steroids and getting that uh clinical remission.
- 1:50:11SPEAKER_04: And then we'll ask uh some questions uh that have been coming in.
- 1:50:16SPEAKER_04: So these are these are really, really good.
- 1:50:18SPEAKER_04: Um in terms of um Anita, I'll start with you pregnancy.
- 1:50:22SPEAKER_04: There was a question that, and I don't know that we have the uh answer specifically.
- 1:50:27SPEAKER_04: Can you cite the number of patients based on trials treated with veto or or aisle 23?
- 1:50:34SPEAKER_04: Um I don't know that I can tell the absolute numbers of patients that have been treated across the trials, but maybe contextualize.
- 1:50:43SPEAKER_04: I think the question gets at veto was an answer that people are using because people are comfortable, it's been out longer.
- 1:50:49SPEAKER_04: Um, and maybe the question's getting at what are the patient years follow-up, which I actually don't know the answer to that, but I don't know if you have any insight on that.
- 1:50:58SPEAKER_08: I don't know the exact number, but uh certainly the the quick way to look at it is monoclonal antibodies or monoclonal antibodies.
- 1:51:05SPEAKER_08: So the science molecularly is the same.
- 1:51:08SPEAKER_08: Call it betolysimab, call it gazilcomab, call it infliximab.
- 1:51:12SPEAKER_08: Um they're monoclonal antibodies.
- 1:51:14SPEAKER_08: So from a pathophysiologic standpoint, the impact to the placenta, to the fetus, to the baby, and to the mother are equivalent.
- 1:51:22SPEAKER_08: So we could be able to interpret as such.
- 1:51:25SPEAKER_04: Good.
- 1:51:25SPEAKER_04: Yeah, I agree, I agree with that.
- 1:51:27SPEAKER_04: Uh Angelina, you mentioned um LFTs and aisle 23.
- 1:51:31SPEAKER_04: Completely agree.
- 1:51:32SPEAKER_04: One of the questions came up, which is interesting.
- 1:51:36SPEAKER_04: Do you switch patients from one aisle 23 to another if there is persistent elevation in LFTs in the first aisle 23?
- 1:51:46SPEAKER_09: I haven't done that.
- 1:51:47SPEAKER_09: I haven't personally done that.
- 1:51:49SPEAKER_09: I don't, I would want to make sure that in the scope of this, um, that what you're really doing is when you are witnessing an LFT elevation, I mean, it's really important to kind of classify this.
- 1:52:01SPEAKER_09: Is this mild?
- 1:52:02SPEAKER_09: Is it less than three times upper limit of normal?
- 1:52:05SPEAKER_09: Is it greater than five times upper limit of normal?
- 1:52:08SPEAKER_09: I mean, it's really important to understand the severity in which this is occurring.
- 1:52:11SPEAKER_09: The second thing you usually want to do is make sure you really understand is it really drug-induced, right?
- 1:52:16SPEAKER_09: Is this a really drug-induced situation?
- 1:52:18SPEAKER_09: Is it getting a little bit more hazy where there may be multiple factors, you know, alcohol, mash, something else that's going on as well.
- 1:52:26SPEAKER_09: So those things probably matter first before I do anything differently.
- 1:52:31SPEAKER_09: So one is to make sure the bottom line is make sure you're attributing the LFT abnormality truly to the drug if you're thinking about switching to another.
- 1:52:39SPEAKER_09: I think that's the best way I would answer it.
- 1:52:40SPEAKER_09: I haven't done that personally.
- 1:52:43SPEAKER_09: I think it could be I mean, it's possible that it would that you we when you withdraw the first drug that you might see the liver enzyme normalized.
- 1:52:53SPEAKER_09: In my in my experience, when I have seen, like you had mentioned this earlier, it's a transient liver enzyme elevation of what I have seen.
- 1:53:01SPEAKER_09: It usually doesn't last beyond the induction period.
- 1:53:03SPEAKER_09: Is you that's typically when I've seen it.
- 1:53:06SPEAKER_09: Um, and it's very mild.
- 1:53:07SPEAKER_09: I haven't, I don't even think I've seen one greater than two times upper limit of normal in my experience.
- 1:53:13SPEAKER_09: Um, and they do normalize.
- 1:53:15SPEAKER_04: Yeah, and I I think the bottom line is we don't have data switching IL-23 one to another, uh, just to be clear, agree with you.
- 1:53:22SPEAKER_04: The other is the LFT abnormality that I look out for with any medicine, but I'll say with IL-103, as long as it's not three times upper limit of normal, above that, um, I still monitor the patient.
- 1:53:36SPEAKER_04: And as Angelina said, look for other reasons their LFTs might be elevated.
- 1:53:40SPEAKER_04: If it's persistently three times or it's gone above that, I do stop that therapy.
- 1:53:45SPEAKER_04: IL23 would be one.
- 1:53:46SPEAKER_04: And if that did happen, I wouldn't switch uh to another.
- 1:53:49SPEAKER_04: Ed, there were some questions on um perenal disease, specifically hydratis, which is out of the context of what we talked about.
- 1:53:57SPEAKER_04: But let me maybe ask it this way for the question that was asking, hydradenitis, um, any data on IL-23 versus TNF, which obviously there's data, but a patient maybe who failed at TNF.
- 1:54:10SPEAKER_04: And then perianal disease in general, you kind of answered this already, but what's your first line, second line therapy?
- 1:54:16SPEAKER_01: Yeah, so I think um I'll go to the second question first because I think Anita alluded to the fact that we need these data to be to be published, and I think that's gonna be very helpful to have that because most of the perianal disease data that we have is in the form of post hoc data from large uh trial programs, and so having dedicated studies is gonna be very helpful.
- 1:54:36SPEAKER_01: So that so sort of putting it in order right now, I think we have influximab as a go-to if they haven't been on influximab, and then it does come down to a JAC inhibitor or IO-23 in my mind, even though there is betilismap data that's been published for perianal disease, I just haven't found that to be as efficacious and or as effective in the real world practice.
- 1:54:54SPEAKER_01: Um, to the point about hydridenitis, I think this is a really interesting question.
- 1:54:57SPEAKER_01: And so, in a patient that's been on an anti-TNF that then is not responding to to um to that anti-TNF therapy and they have bad hydridenitis in the setting of IBD, this is where I think going back to the difference between being in an IBD center and having to have a challenging place like this in practice, I'm really lucky because our dermatologist that manages hydrogenitis happens to be one of the go-to people in the country.
- 1:55:21SPEAKER_01: And so he has trials for this.
- 1:55:23SPEAKER_01: He will put people on combo, if not tertiary, advanced therapies, and he's injecting with methotrexate and he's doing laser therapy weekly.
- 1:55:32SPEAKER_01: So I think this is where I can't tell you there's an algorithm for this, and I think it would be try everything because these are among the most refractory patients that we have.
- 1:55:41SPEAKER_01: And so that's that's the most unreassuring answer that you'll give you on the pillow.
- 1:55:49SPEAKER_01: Except go to UNC to get the other thing.
- 1:55:50SPEAKER_01: Oh, but but my point is I think be once you get beyond standard of care for hydradenitis, you try anything because this is so debilitating for the patient.
- 1:56:00SPEAKER_01: So you just try everything that you can.
- 1:56:01SPEAKER_01: That's what I've seen Dr.
- 1:56:02SPEAKER_01: Saed do.
- 1:56:03SPEAKER_04: So I think one thing with hydradenitis, and then Angelina I'll call on you.
- 1:56:07SPEAKER_04: Sometimal hydradenitis is difficult to distinguish from perianal Crohn's disease.
- 1:56:13SPEAKER_04: Obviously, if a patient has axillary changes of hydradenitis uh in certain other areas of the body, there might be some features that look like hydradenitis, but sometimes we can't tell.
- 1:56:23SPEAKER_04: Like Ed said, I think TNF inhibitor is first line, but then when you get beyond that, probably getting specialists involved.
- 1:56:30SPEAKER_04: But Angelina, your thoughts?
- 1:56:32SPEAKER_09: Well, I was just thinking the same, but I also wouldn't have any concerns with putting someone on an IL-23 if they did have HS either to see if it would improve things, given that it has favorable skin effects as well.
- 1:56:43SPEAKER_09: So I think again, I agree tremendously, this can be extremely challenging uh in the management and improvement.
- 1:56:51SPEAKER_08: So and then there are a few case series and studies with IL-23s as well as with JAX to study and evaluate its role and efficacy in HS.
- 1:57:02SPEAKER_04: Yeah, and I think we've all used probably all the agents.
- 1:57:05SPEAKER_04: Generally, our dermatologists love IL-23.
- 1:57:08SPEAKER_04: So if I'm gonna send a patient the dermatologist, I also I'll start an aisle 23 first because if we didn't, they're definitely gonna do that.
- 1:57:16SPEAKER_04: So if we've done that already at Ed's point, then you get into additional uh therapy.
- 1:57:21SPEAKER_04: Anita, uh people picked up on a uh comment you made, and there are a number of questions related to speed and rapidity of onset.
- 1:57:29SPEAKER_04: We didn't, I didn't show any graphs or data, and I know you were involved in some of the IL-23 study, especially GaselkiMab.
- 1:57:37SPEAKER_04: Talk a little bit about, not only in the data, but in your practice, what you're seeing as far as rapidity and speed of onset with IL-23.
- 1:57:45SPEAKER_08: Yeah, so we're we're actually impressed with the level of rapidity that we're seeing with the IL-23s and with my familiarity and involvement with our galaxy trials, but then we're also looking at gravity, which is the sub Q formulations, and quasar, and looking at rapidity and totality, whether it's UC or Crohn's disease, finding that our data, even though our initial endpoints for Crohn's be it eight or ten weeks or whatever it might be, we were still already seeing the separation even as soon as within week one.
- 1:58:16SPEAKER_08: And so that kind of rapidity is what we had not previously seen with some of our other therapies, and that's where the reassuring component came in.
- 1:58:24SPEAKER_04: Perfect.
- 1:58:24SPEAKER_04: Um, Ed, this is an interesting question.
- 1:58:27SPEAKER_04: I'm gonna ask you a question about high BMI, sub Q Gusel QMab, IV GuscelQMAB.
- 1:58:33SPEAKER_04: Uh, and then Angelina, I'm gonna ask you a question that keeps coming up, but how do you determine which IL-23 you use first?
- 1:58:41SPEAKER_04: But high BMI, um, does that make a difference for you in terms of using sub Q versus IV?
- 1:58:47SPEAKER_04: And and Anita has data can she presented it, but I'll ask you first.
- 1:58:52SPEAKER_01: Yeah, I mean I think that it's uh it's a consideration.
- 1:58:56SPEAKER_01: I think that this has been a consideration, even if we think about anti-TNF therapy and and the idea that some of the trials were done with you know double dosing of adolemimab, for instance, and trying to do higher dosing.
- 1:59:06SPEAKER_01: So I think it definitely is a consideration.
- 1:59:08SPEAKER_01: Um whether or not I think every single patient has to be on an IV approach if they have a high BMI is is I I think not necessarily something that I would do in in practice because of some of the accessibility issues that we talked about before.
- 1:59:21SPEAKER_01: Um so I'll sort of give it a short answer because I know we're short on time.
- 1:59:24SPEAKER_01: And then Anita.
- 1:59:25SPEAKER_08: So we looked at PK data of IV formulation and sub Q formulation and utilized and uh studied different factors and variables, and actually BMI did not influence the bioavailability, meaning you could give sub Q despite their BMI.
- 1:59:40SPEAKER_04: Right.
- 1:59:41SPEAKER_04: And if you look at the inter-quartile BMI high and then down the three quartiles, sub Q and IV were indistinguishable in terms of efficacy.
- 1:59:50SPEAKER_04: So kind of that thought out of we have to use IV for high BMI, uh, we didn't necessarily see that.
- 1:59:57SPEAKER_04: Which IL-23 first and why?
- 1:59:59SPEAKER_04: Again, is it's I know we've answered it, but answer it maybe one more time, Angelina.
- 2:00:04SPEAKER_09: Yeah, I think this is where you want to use if there is head-to-head data.
- 2:00:07SPEAKER_09: I think it helps a little bit just thinking.
- 2:00:09SPEAKER_09: Well, let me tell let me say it differently.
- 2:00:12SPEAKER_09: I use the data from sequence, I use the data from the um from the Casalkimab study, looking at Eustachiniumab and seeing that both of those studies showed superiority to Stellara, and then looking at Mirachismab having non-inferiority.
- 2:00:26SPEAKER_09: So to me, that's showing something a little bit different here.
- 2:00:28SPEAKER_09: Whether this makes any sense or not, I don't know, but in my mind, that is something, those are some things that I'm thinking about.
- 2:00:35SPEAKER_09: I like for a lot of the patients, and except for the few that are needing IV, the sub Q induction dosing has been really helpful in a lot of ways.
- 2:00:43SPEAKER_09: So lately that has been a go-to for me.
- 2:00:46SPEAKER_09: In the end, we don't have head-to-head between, say, Risenchizimab and Gasalchimab, so I don't, I can't necessarily say this is the one to use.
- 2:00:54SPEAKER_09: So I think you're you're good in thinking about what you can get for your patient.
- 2:00:59SPEAKER_09: We don't want to have delays in therapy because of some small thing.
- 2:01:03SPEAKER_09: So getting a patient on drug quickly with patient assistance is fantastic.
- 2:01:09SPEAKER_09: And so for me, it's often uh been that I've been writing quite a bit of gus lately.
- 2:01:14SPEAKER_04: And then uh Anita, same question.
- 2:01:16SPEAKER_04: I know you've said it before, but any differences in what you said before?
- 2:01:20SPEAKER_09: No.
- 2:01:21SPEAKER_09: All right.
- 2:01:21SPEAKER_04: And then I'll end with one question.
- 2:01:23SPEAKER_04: I'll need to come back to you and Ed I'll end.
- 2:01:25SPEAKER_04: We can't get through any program without talking about GLP1, so thank you.
- 2:01:29SPEAKER_04: There were a bunch of GLP1 questions.
- 2:01:33SPEAKER_04: Um, just for the record, we don't have enough data.
- 2:01:36SPEAKER_04: Ed, you might talk a little bit about the pauchitis data with GLP1s.
- 2:01:40SPEAKER_04: Um, one, Anita, is there any problem using any of our therapies in a patient on a GLP1?
- 2:01:47SPEAKER_04: And two, are you using GLP1s to treat IBD specifically?
- 2:01:51SPEAKER_04: Completely off label, not part of this uh actual program, but just to ask those two questions.
- 2:01:58SPEAKER_08: Am I using GLP personally?
- 2:01:59SPEAKER_08: No, I'm kidding.
- 2:02:00SPEAKER_08: Uh I didn't say that.
- 2:02:03SPEAKER_03: Free conversation.
- 2:02:05SPEAKER_08: Um so no harm in continuing or starting or initiating appropriate therapy for your patient, even if they're on a GLP.
- 2:02:13SPEAKER_08: In fact, you're probably going to have better outcomes because we know obesity and some of those other medical comorbidities related to that.
- 2:02:20SPEAKER_08: If we could improve that, because obesity fat adipose is inflammatory, we're also seeing better benefits and disease control.
- 2:02:28SPEAKER_08: In fact, I believe Mary Kizimab actually has a trial and study with uh GLP and Mary.
- 2:02:34SPEAKER_08: Uh so, or they're evaluating.
- 2:02:35SPEAKER_08: I don't know if that's uh taken off.
- 2:02:37SPEAKER_08: Um your second question as far as to use it as a solo, no.
- 2:02:42SPEAKER_01: Okay.
- 2:02:43SPEAKER_01: Ed?
- 2:02:44SPEAKER_01: Yeah, no, I totally agree.
- 2:02:45SPEAKER_01: And I think that, you know, the specific way that we have used the GLP1s, and and this comes up um in our pouch clinic, is that it in uh aside from the inflammatory component, patients that have an iliop anal anastomosis have a J pouch often have high bowel frequency that's separate from actually the inflammatory component of having pouchitis or Crohn's like disease of the pouch.
- 2:03:06SPEAKER_01: And what GLP1 is mediated in is the iliocolonic break.
- 2:03:10SPEAKER_01: So if you have a don't have a colon anymore, then obviously you lose that, and that may be one of the drivers of high bowel frequency.
- 2:03:15SPEAKER_01: And so GLP1 receptor agonist therapy can actually help in slowing down bowel frequency.
- 2:03:20SPEAKER_01: And so we did a small pilot trial at UNC where Hans Herfarth led it where patients were on active therapy and randomized to placebo or placebo and randomized, and there was self-control and randomized to active therapy, and showed over a 30% decrease in bowel frequency during a very short uh trial.
- 2:03:35SPEAKER_01: And so we've now used that to then get approval for these therapies in a large proportion of our patients in our pouch clinic.
- 2:03:42SPEAKER_04: But just again, fair balance.
- 2:03:43SPEAKER_04: We're not recommending GLP1 as a sole treatment for IBD, but we are completely comfortable if a patient's on a GLP1.
- 2:03:51SPEAKER_04: And as Anita said, there are studies that are now being designed to use GLP1 as part of the therapy for IBD.
- 2:03:58SPEAKER_04: Um, Ed, Angelina, Anita, thank you.
- 2:04:01SPEAKER_04: I thought that was very interactive and excellent.
- 2:04:03SPEAKER_04: To the audience in the room and the audience online, thank you for so many questions.
- 2:04:07SPEAKER_04: Sorry we couldn't get to them.
- 2:04:09SPEAKER_04: For those here, enjoy the rest of Congress.
- 2:04:11SPEAKER_04: And I know with the snowstorm out there, I wish everybody safe travels back.
- 2:04:15SPEAKER_03: See you around here.